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ABSTRACT 
 
The accumulation of the microtubule associated protein tau has been implicated 
in several neurological disorders; however, its interaction with chaperones along 
its normal degradation pathway remains largely uncharacterized at single residue 
resolution. In this study, nuclear magnetic resonance (NMR) spectroscopy was 
used to probe the interaction between tau, the molecular chaperone Hsp90, and 
the immunophilin FKBP51. Resonance intensity changes were observed for 
specific residues in the heteronuclear single quantum coherence (HSQC) spectra 
of 15N-labeled tau in the presence of Hsp90 and/or FKBP51. Analysis of the 
HSQC spectra identified the two hydrophobic hexapeptide motifs located at 
residues V275 – K280 and V306 – K311 in tau’s C-terminal assembly domain as 
the sites of an interaction with both Hsp90 and FKBP51. Resonances that show 
reduced intensities did not experience line broadening, which suggests that slow 
chemical exchange is occurring with a bound conformation that is not observable 
due to the molecular weight of the complex. We have also investigated the role of 
the PPIase domain alone in binding to tau and found that specific residues within 
the PPIase active site experience significant reductions in intensity upon addition 
of tau. The experimental data is collectively used to propose a structural model 
for ternary complex formation between tau, Hsp90, and FKBP51. 
vii 
 
  
CHAPTER ONE: INTRODUCTION 
Overview of tau biology 
The microtubule associated protein tau is localized in the axon tracts of 
normal neuronal cells and is also an intrinsically disordered protein (IDP) [1-4]. 
Microtubule associated proteins function as structural proteins of larger 
cytoskeletal components and are capable of stimulating neuronal growth and 
development [1,4]. Tau normally functions to bind microtubules (MTs) in the brain 
and facilitates the stable outgrowth of MT bundles in the axon tracts of 
developing neurons [1]. Historically speaking, it was not until 1986 that Ihara et 
al., and Kosik et al. determined that neurofibrillary tangles (NFTs) found in the 
brain were composed of tau protein [9,10]. In fact, contemporary studies around 
the same time were the first to reveal that paired helical filaments (PHFs), 
precursors to NFT formation, contained abnormally high levels of phosphorylated 
tau protein [11,12]. 
When tau becomes phosphorylated it will dissociate from MTs, becoming 
available to enter into its normal degradation pathway. Failure to degrade and 
recycle higher order tau aggregates leads to the formation of NFTs [13,14]. It is 
normal for tau to naturally accumulate in our brains as we age, however; toxic 
NFT formation leads to neurodegenerative defects seen in patients with 
Parkinson’s disease, frontotemporal lobe dementia, Alzheimer’s disease (AD), 
1 
 
 
and other diseases commonly termed “taupathies” [12,15-17]. As many 
disordered proteins have been shown to be involved in a bevy of human 
diseases [18], it is not surprising that tau plays such a prominent role in many 
neurodegenerative disorders.  
 Protein aggregation is the underlying mechanism behind abnormal tau 
accumulation because it can effectively halt the maintenance of protein 
homeostasis [19,20]. Molecular chaperones can function to abrogate protein 
aggregation by refolding misfolded proteins and promoting the clearance of 
aggregates through association with other proteins involved in the proteasomal 
and/or lysosomal degradation pathways [21].  
Structure and function of the microtubule associated protein tau 
The tau gene is located on chromosome 17q21 and is comprised of one 
non-coding and 14 coding exons [16,22]. Figure 2 demonstrates that alternative 
splicing of exons 2, 3, and 10 results in one of six possible tau isoforms that can 
be grouped into two general categories; those containing three MT-binding 
repeat domains (isoforms 2N3R, 1N3R, and 0N3R) and those containing four 
MT-binding repeat domains (2N4R, 1N4R, and 0N4R) [22,23]. Regulating tau 
expression in this way plays an integral role in the expression of disease 
phenotypes and will alter the normal function of neurons in the brain. 
Although the 0N4R tau isoform is considered entirely disordered, the C-
terminal assembly domain, comprised of four MT-binding repeats, is distinctly 
different than the N-terminal projection domain. The N-terminal domain (residues 
1-200) is highly dynamic and has a significantly lower amount of transient 
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secondary structure when compared to the C-terminal assembly domain 
(residues 201-441) [24]. Although this can be partially attributed to the high 
percentage of acidic residues in the N-terminal domain of tau, the presence of 
repeats in the C-terminal assembly domain creates sequential regions of 
transient secondary structure near the MT-binding repeats that leads to a 
decrease in rotational correlation time and a corresponding decrease in 
dynamics around those regions [24]. The projection domain is not needed for tau 
to associate with microtubules; however, the presence of variable exons in this 
domain does play some role in developmental regulation [23-25].  This domain is 
also where the majority of disease-causing mutations in the tau gene reside, 
further belying its importance both in tau function and pathogenicity [15,16,26]. 
 
Figure 1. Schematic representation of 0N4R tau. Although tau is intrinsically disordered, it has 
been shown to form some transient secondary structure in the presence of MTs and other 
polyanions [33]. Residues 44-103 do not exist in the 0N4R tau construct due to alternative 
splicing. This schematic highlights hexapeptide V275 – K280 and hexapeptide V306 – K311 in 
tau’s C-terminal assembly domain and their relative positions preceding MT binding repeats R3 
and R4, respectively. These two regions exhibit the highest degree of transient beta sheet 
structure. The V275-K280 hexapeptide has a fractional content of beta-sheet structure 
representing 22% of the total population and hexapeptide V306-K311 has a fractional content of 
beta-sheet structure representing 25% of the total population  [31,33]. 
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Intrinsically disordered proteins in disease 
In general, intrinsically disordered proteins are characterized as having a 
dynamic, extended non-globular structure capable of adopting a broad range of 
ensembles [27-33]. The lack of tertiary structure and the ability to adopt 
numerous conformations allows for binding promiscuity with many distinctive 
protein partners or ligands across various cell types [34,35]. IDPs are common in 
the proteomes of all species and play prevalent roles in diseases such as cancer 
and Alzheimer’s [18,36]. In terms of evolution, the abundance of IDPs in 
eukaryotes (predicted to be 15-45% of total proteome) is most likely a result of 
the increased need for cell signaling and gene regulation in more complex 
Figure 2. Schematic representation of alternative splicing in the q21 locus of chromosome 
17. Alternative splicing on exons 2, 3, and 10 in the q21 region gives rises to different tau isoforms 
of various lengths. The 0N4R construct used here (highlighted in green) contains all four MT-
binding repeat domains and is 383 amino acids long. 
4 
 
 
systems [29,34]. Figure 3 shows a plot of the residue specific disorder tendency. 
 
When studied experimentally, IDPs have displayed high specificity and 
low affinity for their respective binding partners and are overrepresented in 
protein families that are involved in transcription, translation, signal transduction, 
and cell cycle regulation [28,30,34,37]. Although IDPs have a disordered native 
state, they can adopt a relatively rigid structure in the presence of a ligand 
through a process termed coupled folding and binding. This mechanism involves 
the transition from disorder to order upon association with a binding partner 
[27,28,30]. When tau associates with itself, the more pronounced transient beta-
sheet structure in the assembly domain has been shown to lend itself to the 
formation of aggregates in the brain. More specifically, tau’s normal function of 
binding and stabilizing MT bundles can be affected by its ability to form transient 
beta-sheet structure in the C-terminal assembly domain [38]. 
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Figure 3. IUPRED Disorder prediction of 0N4R tau. This plot represents the disorder tendency 
of 0N4R tau. Anything above the redline at 0.5 is predicted to be disordered [5].  
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The function of tau can also be regulated by altering its phosphorylation 
status resulting in dissociation from MT bundles [25,39]. Tau has over 75 
possible phosphorylation sites that are regulated by a host of different kinases 
and phosphatases [40,41]. In particular, microtubule associated protein kinases 
and cyclin dependent kinases have been shown to phosphorylate serine and 
threonine residues along the MT-binding domains of tau [25,42-44]. NFTs 
containing tau protein have been shown to contain a high amount of the 
phosphorylated tau species, relative to unphosphorylated tau [25,45]. It is 
phosphorylated tau that is thought to interact with co-chaperones along its 
normal processing and degradation pathway in vivo. Molecular chaperones that 
participate in the processing, recycling, and degradation of tau have been 
implicated in the formation of NFTs [46-51]. Specifically, Hsp90 and its co-
chaperone FK506 Binding Protein 51 (FKBP51) have been shown to regulate the 
status of tau and directly effect levels of both the total and phosphorylated 
species of tau in the brain [45,50]. 
The role of molecular chaperones in tau processing 
Defining the interaction between tau and proteins along its degradation 
pathway is important to unraveling the molecular mechanism by which it is 
processed. Molecular chaperones such as Hsp90 are abundant in brain tissue 
and are capable of recruiting client proteins to assist along the processing and/or 
degradation pathway [45,52,53]. Typically, co-chaperone complexes containing 
Hsp90 can bind a variety of clients with different functions [20,54,55]. FKBP51 
assists in recruiting client proteins like tau to the co-chaperone complex and can 
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even alter the ATPase activity of Hsp90 [19,20]. Although tau is abundant in the 
brain and naturally accumulates as we age, its physiological concentration 
relative to Hsp90 and FKBP51 is not known [56].  In recent years, Hsp90 and 
FKBP51’s role in the brain have been studied for their relevance to 
neurodegenerative disorders such as AD. In 2010, Dickey et al. showed through 
co-immunoprecipitation studies that FKBP51 co-localizes with Hsp90 and tau in 
the axon tracts of developing neuronal cells, suggesting evidence for the physical 
interaction of these proteins in vivo. The same study also found that siRNA 
knockdowns of FKBP51 reduced tau levels, while FKBP51 overexpression 
enhanced the association of tau with Hsp90 – promoting clearance of aggregates 
and the outgrowth of microtubules [45]. A surface image of the Hsp90 dimer is 
presented in Figure 4 and was prepared using Pymol [57]. 
FKBP51 is an immunophilin and  has PPIase activity 
The immunophilin family of proteins are typically categorized into the 
FK506 binding proteins and those that bind cyclosporin A, with both of these sub 
families showing peptidylprolyl cis/trans isomerase (PPIase) activity [58-60]. 
PPIases get their name because they catalyze a reaction that accelerates the 
folding of proteins for which the rate determining step involves the  isomerization 
from the trans to cis conformation of proline peptide bonds [61,62]. The PPIase 
activty of FKBP51 rests within the FK1 domain with a requirement for residues 
F67 and D68. Part of this study will focus on providing novel nuclear magnetic 
resonance (NMR) spectroscopy data regarding the PPIase domain (FK1) of 
FKBP51 as well as how this domain may interact directly with tau.  
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Previous evidence has shown that a similar PPIase, Pin1, is able to 
interact with tau and modulate phosphorylation through an interaction with 
protein phosphatase A [63,64]. It is proposed that Pin1 may interact with tau and 
catalyze an isomeric change to the trans conformation – thereby facilitating a 
phosphorylation event, although the specific mechanism remains ambiguous 
[63]. Pin1’s ability to regulate dephosphorylation with the assistance of protein 
phosphatase 2A combined with its inherent PPIase activity is similar to that of 
FK1; except that Pin1 lacks the Hsp90-interacting tetratricopeptide repeat (TPR) 
domain present in the full length protein, FKBP51 [6]. The domain structure of 
FKBP51 is highlighted in Figures 5.It is believed that Hsp90 and FKBP51 form a 
co-chaperone complex that regulates the recycling of tau. It is thought that the 
90° 
Figure 4. Crystal structure of Hsp90 dimer. Cartoon surface representation of the Hsp90 
dimer (derived from PDB ID: 2CG9). Different colors indicate respective Hsp90 monomers in 
the larger dimer. Co-chaperone complexes containing Hsp90 can bind a variety of client 
proteins [8].  
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association between FKBP51, Hsp90, and tau collectively functions as a co-
chaperone complex and acts as a mechanism for normal degradation and 
recycling of tau [45,65]. Interestingly, recent cellular studies by Dickey et al. in 
2010 have shown that an siRNA knockdown of FKBP51 leads to a reduction of 
tau levels in neuronal tissue – indicating better clearance of tau aggregates. 
Conversely, their results show that when FKBP51 is overexpressed in neuronal 
cells it appears to have a neuroprotective effect; preserving tau and preventing it 
from degrading normally. Although FKBP51 has been shown to interact with tau 
via co-immunoprecipitation assays, a physical binding event at single residue 
resolution has yet to be documented [45]. FKBP51 is also unique among the 
FKBPs because it possesses the ability interact with Hsp90 via a TPR domain, a 
feature not present in all other FKBPs [7,66,67]. This interaction is highlighted in 
180° 
Figure 5. Domain structure of two FKBP51 monomers. Cartoon surface representation of FKBP51 
(derived from PDB ID: 1KT0). Colors indicate the three domains of full length FKBP51 – FK1 (purple), 
FK2 (blue), and the TPR domain (green) [7].  
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Figure 6. Although a similar FKBP, FKBP52 contains 60% sequence similarity 
with FKBP51 and includes a TPR domain, cellular studies have demonstrated to 
have opposite effects on tau regulation - a dichotomous relationship between the 
function of FKBP51 and FKBP52 [66,67]. 
Structural considerations of the Hsp90 – FKBP51 co-chaperone complex 
Previous studies have shown that the TPR domain on FKBP51 associates 
with the MEEVD recognition site in the C-terminus of Hsp90. During a study in 
2001 looking at the association of known PPIases with Hsp90, Buchner and 
colleagues determined that Hsp90 and FKBP51 bind tightly, with a Kd of 174nm 
[67]. In terms of regulating protein homeostasis in vivo, the PPIase activity 
present in the FK1 domain of FKBP51 has been shown to promote tau stability 
and improve microtubule integrity [6,45,67]. PPIase activity is particularly 
important in terms of tau biology as cellular studies have shown PPIase deficient 
mutants of FKBP51 show higher percentages of phospho-tau and total tau 
aggregates in vivo [45]. Understanding how a co-chaperone complex comprised 
Figure 6. Cartoon model of Hs90 – FKBP51 complex. This cartoon representation of the 
Hsp90 – FKBP51 co-chaperone complex highlights the interaction between the TPR domain of 
FKBP51 and the MEEVD sequence on Hsp90. 
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of one Hsp90 dimer will associate with FKBP51 and  interact with tau will 
facilitate our understanding of how tau aggregation may be regulated by 
molecular chaperones. 
Project Summary and Specific Aims  
The microtubule associated protein tau, is localized in the axon tracts of 
normal neuronal cells. Although tau normally functions to bind and stabilize 
microtubules, failure to degrade and recycle higher order tau aggregates has 
been shown to cause neurodegeneration – a feature common in other 
neurodegenerative diseases termed “taupathies”. Hsp90 and FKBP51 are 
proteins believed to form a co-chaperone complex with tau [45]. This interaction 
likely helps regulate the phosphorylation status of tau and promote its stability or 
degradation [65,68]. Tau is also an intrinsically disordered protein and further 
characterization of its structure and dynamics could shed light on other diseases 
involving disordered proteins. If we understand the mechanism by which tau 
interacts with Hsp90 and FKBP51 during its processing, we can better define 
how this interaction abrogates tau aggregation in the brain.  
The proposed studies focus on the interaction between tau, FKBP51, the 
PPIase domain of FKBP51, and Hsp90. Recent evidence has been presented 
suggesting that there is an increase in both total tau and phospho-tau levels in 
vivo when FKBP51 is overexpressed in an AD mouse model [45]. As full length 
tau is intrinsically disordered and is not a candidate for crystallography, NMR 
spectroscopy is the best available method to investigate the specific interaction 
taking place between tau and its co-chaperone complex. Comparison and 
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characterization of NMR chemical shift data for tau in both free and bound to 
Hsp90 and/or FKBP51, will allow us to determine the specific regions on tau 
involved in binding. We propose that by characterizing the structure, dynamics 
and interactions of tau in the presence of co-chaperones Hsp90 and/or FKBP51, 
we will be able to better define how a ternary complex is formed. The specific 
aims are: 
 
Specific Aim 1: Probing the NMR structure and dynamics of tau and 
FKBP51. Using NMR spectroscopy we will collect chemical shift data on the 13C-
15N-labeled FK1 domain of FKBP51. Titration experiments will be designed 
between FK1 and FK506 and FK1 and tau, and the perturbations of assigned 
chemical shifts will be monitored. 
Specific Aim 2: Investigating formation of a ternary complex between tau, 
FKBP51, and Hsp90. Using NMR spectroscopy we will collect chemical shift 
data for 15N-labeled tau in order to characterize the structural implications of the 
interaction between tau in the presence of Hsp90 and/or FKBP51. Resin binding 
assays and MD simulations will also be employed to assess ternary complex 
formation. 
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CHAPTER TWO: PROBING THE STRUCTURE AND DYNAMICS OF TAU AND 
FKBPB51 
Rationale and Experimental Design 
Recent studies have reported the abundance of FKBP51 in normal brain 
tissue as well in AD brains, resulting in a renewed focus on the determination of 
its role in neuronal function [45,69-72]. We anticipate that the activity of the 
PPIase domain in full length FKBP51 affects the normal aggregation of tau and 
contributes to the formation of higher order aggregates. Our interest in the 
PPIase domain of FKBP51 stems from evidence suggesting that a PPIase 
deficient mutant of FKBP51 (F130A) fails to prevent tau from being digested and 
recycled, leading to a significant increase in total tau levels [45]. This mutant has 
also been shown to decrease the length of microtubules in neuronal tissue 
relative to wild type FKBP51 [45].  
We are suggesting that there are specific binding regions contained within the 
PPIase domain of FKBP51 that are capable of interacting with tau. Previous 
evidence has shown that the PPIase active site/FK506 binding domain is 
conserved among many FKBPs, and it is likely that we will see some chemical 
shifts in this region [62,73]. As mentioned previously, the PPIase domain may 
also be involved in regulating phosphorylation events, although that is not the 
focus of this study. In order to assess secondary structure elements present in 
13 
 
 
FK1, it was necessary to first perform a HNCACB NMR experiment on the free 
FK1 domain. This allowed us to make resonance assignments for each non-
proline residue on the protein. Once resonances assignments are made, a peak 
list is generated that contains a list of chemical shifts for the amide proton, amide 
nitrogen, alpha carbon, and beta carbon for each residue. These chemical shifts 
are available in Table 1 located in Appendix A. 
Sample Preparation of 15N-labeled FK1:  
Gel Notes:    
1. MW 
2. Pre Induction 
3. Post Induction 
4. Pre Induction 
5. Post Induction 
6. Pellet 
7. Supernatant 
8. Co Flow Through Fractions 
9. Co Wash Fractions 
10 – 15. Co Elution Fractions 
 
75 kD--  
50 kD-- 
 
 
37 kD-- 
25 kD-- 
 
 
20 kD-- 
 
1     2     3     4      5    6    7     8     9   10   11    12   13    14    15 
 
Gel Notes:  
  
16. Pre Cleave 
17. 5hr Cleavage Time Point 
18. 4hr Cleavage Time Point 
19. 3hr Cleavage Time Point 
20. 2hr Cleavage Time Point 
21. 1hr Cleavage Time Point 
 
16      17     18     19     20     21     
 
A 
Figure 7A. Purification workflow for FK1. (A) Two gel image for initial affinity Cobalt column (eluted 
at 3.0 mL/min), and post-cleavage affinity Cobalt column (eluted at 3.0 mL/min), respectively. 
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3D NMR experiments with 13C15N-labeled FK1 
Following the optimization of the purification protocol for FK1, a 13C15N-
labeled protein sample was created using stable metabolic incorporation of 
isotopic labels. Three neighboring spin systems of the HNCACB spectrum for the 
13C15N-labeled FK1 spectra are shown in Figure 8 below. Once assigned, we can 
determine the presence of secondary structure by comparing our chemical shifts 
to standard chemical shift values [74]. All information regarding the NMR data 
acquisition and processing can be found in the Methods section.   
Making resonance assignments 
When making new resonance assignments it is necessary to be familiar 
with the sequence around the region you are assigning. Correlating Cα and Cβ 
chemical shifts from HNCACB spectra can provide information regarding the 
 
75 kD--  
50 kD-- 
 
37 kD-- 
25 kD-- 
 
20 kD-- 
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Figure 7B. Post-cleave purification workflow for FK1. (A) Post SEC (eluted at 1.0 mL/min) 
and gel of final concentrated FK1 NMR sample at 0.483m, respectively. 
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backbone structure of the protein of interest. As demonstrated in Figure 8, the 
positions of the chemical shifts of Cα and Cβ in each spin system of the FK1 
spectra can be correlated to determine the particular amino acid in and the spin 
system it corresponds to. The HNCACB requires the protein to have both 
magnetically labeled N and C atoms and the experiments are designed so that 
radio frequency pulses induce a resonance effect on the amide proton that is 
transferred through the covalent bonds to the N, Cα and Cβ atoms and back, 
yielding a signal with resonances in the corresponding frequencies [75]. This 
allows spectra to be generated in three dimensions with the 1H, 15N, and 13C 
Figure 8. Neighboring spin systems in FK1 HNCACB spectra. This image displays 
screenshots of neighboring spin systems from spectra used to correlate resonances of L128, 
F129, and F130 in the FK1 HNCACB spectra. 1H, 13C, and 15N represent the x, y, and z axes, 
respectively. Red and blue resonance indicate Cα and Cβ, respectively. 
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making up the x, z, and y axis respectively. The strongest carbon signal will 
always come from Cα and Cβ atoms of residue i, however; for the HNCACB a 
weaker resonance coming from the previous residues’ C atom, Cβ, can also be 
detected in residue i-1. This allows for the correlation of spin systems within the 
group of spectra generated from the HNCACB, allowing for a more high definition 
picture of the backbone of the protein.  
In the example provided for FK1 in Figure 8, three neighboring spin 
systems are show in Figure 8. In the far right spin system for F130, there are 
stronger resonances for the alpha and beta carbons corresponding to residue 
F130 (i), and weaker resonances that corresponds to the preceding residue, 
F129 (i-1). Spin systems can be connected in this way to eventually correlate 
each atom for each residue of the protein [75].  
 Examining secondary structure in FK1 
Figure 9. Secondary chemical shift values for the PPIase domain of FKBP51. Values were 
determined by comparing differences of experimental chemical shifts to standard Peter Wright 
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random coil values [74]. The Y axis shows the difference   between observed   and   expected 
chemical shift values. Groupings of three or  more residues with chemical  shift values greater 
than or less than  0.7 ppm  correspond to predicted α-helix and β-sheet secondary structures, 
respectively. A full list of chemical shift values for FK1 can be found in Appendix B. Results 
confirm general structure of five beta sheets surrounding a central alpha helix. 
2D NMR experiments with 15N-labeled FK1 
In order to further characterize the binding activity of the PPIase domain in 
the presence of natural product FK506 and also in the presence of tau, an 
heteronuclear single quantum coherence (HSQC) spectrum was collected for 
free 15N-labeled FK1 and is shown in Figure 10. This initial HSQC spectrum can 
easily be used as a benchmark such that once aother HSQC spectrum is 
collected we are able to assess chemical shift and/or intensity changes of 
resonances undergoing chemical exchange. In order to investigate our 
hypothesis, we analyzed the different positions and/or intensities of peaks 
between free FK1 and FK1 bound to FK506. The HSQC for FK1 in the presence 
of FK506 is shown in Figure 11. The rationale behind performing a titration 
between FK1 and FK506 prior to FK1 and tau was that because it is a well 
characterized interaction, the bound state profile of FK1 may shed some light on 
determining which residues on FK1 are likely to be involved in binding to tau. 
FK1 was prepared as previously described and tau sample preparation is listed 
at the beginning of chapter three. 
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Characterization of FK1 binding to FK506 
 There have been many studies in the past focused on the interaction 
between the FKBP class of immunophilins and FK506 [7,59,70]. However, the 
interaction between FKBP51 and FK506 has yet to be characterized using NMR 
spectroscopy. In previous crystallographic studies, some residues have been left 
out of the crystal structure because of their inherent disorder. Because NMR is 
able to characterize poorly structured regions of proteins, we will be able to 
characterize the structural change that occurs across all residues when FK506 
binds to the PPIase domain of FK1 [76-78]. The natural product and 
immunophilin ligand FK506 is commercially available from Sigma Aldrich (U.S.A.) 
Figure 10. 1H15N HSQC for free 15N-labeled FK1. This assigned HSQC of FK1 in the free state 
will be used as a benchmark to measure any chemical shifts or intensity reductions for 
resonances upon addition of a potential binding partner. 
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and was titrated into the 15N-labeled FK1 sample. Figure 11 shows an overlay of 
free 15N-labeled FK1, and 15N-labeled FK1 in the presence of FK506. Figure 12 
shows a difference plot of normalized chemical shifts for each assigned residue 
on FK1 between the free and bound states, respectively. Figure 13 shows an 
image has also been generated using Pymol that assists in visualizing the 
correlation between the change in normalized 1H and 15N chemical shifts (Figure 
12) and the location of the conserved binding pocket in the crystal structure of 
FK1 bound to FK506.  
 The proton and nitrogen chemical shifts in Figure 12 were combined and 
normalized using the equation shown in the figure legend. The mean normalized 
chemical shift was calculated (0.055) for all assigned residues and the red line in 
Figure 12 indicates one standard deviation above the mean value (0.10). Those 
chemical shifts that are above the red line indicate resonances experiencing 
significant chemical shifts, relative to the mean, upon addition of FK506. It is not 
surprising that these zones are inside and around the binding pocket as shown in 
Figure 13A and B. Figure 13C show that the backside of the FK1 domain is 
almost entirely grey, demonstrating that most of the changes, in general, are 
occurring near the PPIase active site.  
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Figure 11. 1H15N HSQC 15N-labeled FK1 in the presence of FK506. Overlay of two HSQCs of 
FK1 in the free state (black resonances) and FK1 bound to FK506 (red resonances). 
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 Figure 12. Normalized 1H15N FK1 chemical shift differences between free FK1 and FK1 
bound to natural product FK506. 1H and 15N chemical shift differences for free FK1 and FK1 in 
the presence of FK506 were normalized together and plotted. One standard deviation above the 
mean value is indicated by the red line and was calculated from the mean (.056) of the 
normalized chemical shifts for all residues. Normalization equation: √(𝐻1−𝐻2)2+(𝑁1−𝑁2)2/5
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Figure 13. Surface representation of regions on FK1 that 
experience significant chemical shift changes in the presence 
of FK506. (A) Displays a surface representation of FK1 bound to 
FK506, however; FK506 has been removed to show the conserved 
binding pocket in FK1. Gray indicates regions or residues of 
normalized 1H and 15N chemical shift values below the mean. Blue 
indicates regions or residues with normalized chemical shifts 
between the mean value and one standard deviation above the 
mean (0.106) and red indicates normalized chemical shifts that are 
greater than one standard deviation above the mean. (B) Displays 
a surface representation of FK1 bound to FK506 with FK506 
included (green) [6]. (C) Shows the backside (180ᵒ rotation) of FK1 
and indicates a lack of intensity changes. 
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Characterization of FK1 binding to tau 
Following spectral analysis between FK1 in the free state and in the 
presence of tau, we determined that there are no significant global chemical shift 
changes observed in the spectra. This overlay is shown in Figure 14A. However, 
there are several important residues that experience changes in intensity and/or 
experience a small chemical shift. The largest chemical shift occurs for residue 
I87, which is shown in Figure 14B. Analysis of resonance intensities revealed an 
important pattern. Figure 15 shows an intensity ratio plot for free FK1 and FK1 in 
the presence of tau. The plot demonstrates that there are not very many regions 
that are undergoing significant intensity reductions, however; there are specific 
residues that are undergoing significant changes. In a normal binding interaction 
there are typically shorter regions of amino acids (3-6 residues) that are involved 
in binding. In this case, the only residues that collectively experience an intensity 
reduction at or greater than one standard deviation above the mean occur in one 
or two residue gaps. Interestingly, these residues are within regions shown to 
have strong beta sheet structure determined by our HNCACB experiments 
(Figure 9) and are also important when FK1 binds to its natural product FK506. 
The aspartic acid at position 68 experiences the largest reduction in intensity 
upon addition of tau and is directly linked to PPIase rotamase activity [6,62]. 
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I87 
B 
A 
Figure 14. 1H15N HSQC of FK1 in the presence of tau. (A) Overlay of two 2D HSQC of FK1 in 
the free state (blue resonances) and FK1 in the presence of 0N4R tau (red resonances). (B) 
Residue I87 is in the PPIase active site and experiences the largest chemical shift. 
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 Figure 15. Intensity ratio plot of 15N-labeled FK1 in the presence of tau. The residue that 
experiences the largest reduction in intensity upon addition of tau is D68. Specifically, H56 and 
K58, K60 and L61, and D68, F77, S69 and I87, all show reductions more than are one standard 
deviation outside of the mean. The red line on indicates one standard deviation below the mean 
and was calculated from the average intensity ratios for all assigned residues. Gaps indicate 
unassigned or missing resonances. Red stars correspond the red region in Figure16 that 
experiences the largest changes upon addition of tau. 
Analysis of resonance intensity ratio plot for 15N-labeled FK1 
 Despite the lack of large regional changes seen in the intensity ratio plot in 
Figure 15, the results show that several residues within the PPIase active site 
(50-130) do individually undergo significant reductions. Specifically, H56 and 
K58, K60 and L61, and D68, F77, S69 and I87, all show reductions more than 
one standard deviation outside of the mean. As these residues are within the 
region that forms a cleft near residue 68, it is logical that a weak interaction with 
tau may be taking place in this ready-made pocket. In fact, the initial crystal 
structure of FK1 bound to FK506 identified several of these residues as important 
in binding to FK506 [6]. Although D68 has been shown to specifically confer 
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PPIase activity, the surrounding residues play an important role in positioning the 
ligand into the binding site. The results presented here demonstrate that 
previously identified residues important for binding FK506 may also be important 
for binding to tau, as see in Figure 16 below. The presence of the FK2 and TPR 
domain may need to be present in order to facilitate a stronger association 
between the FK1 domain and tau. Although it is beyond the scope of this project, 
phosphorylated tau species may very well interact differently with FK1 than 
unphosphorylated tau. 
   
Figure 16. Surface representation of regions on FK1 that undergo a weak interaction with 
tau. Regions colored red indicate residues that experiencing the most significant intensity 
reductions. Red stars from Figure 15 correspond the PPIase active site seen in red here [6]. 
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CHAPTER THREE: ASSESSING FORMATION OF A TERNARY COMPLEX 
BETWEEN TAU, HSP90, AND FKBP51 USING NUCLEAR MAGNETIC 
RESONANCE SPECTROSCOPY 
Rationale and Experimental Design 
Tau is an intrinsically disordered protein that binds tubulin in order to 
facilitate the stabilization and outgrowth of microtubule bundles in the axon tracts 
of normal neuronal cells [1-4]. Although tau’s specific mechanism of processing 
and degradation in the brain remains ambiguous, it is clear that improper 
processing of tau by molecular chaperones can lead to the accumulation of 
aggregates resulting in the formation of neurofibrillary tangles. These tangles are 
one of the factors implicated in over 15 neurodegenerative disorders, including 
Parkinson’s disease, frontotemporal dementia, and Alzheimer’s disease (AD) 
[12,15-17]. Molecular chaperones that participate in the processing, recycling, 
and degradation of tau have been implicated in the formation of neurofibrillary 
tangles [51,79-83]. In particular, the molecular chaperone Hsp90 and its co-
chaperone FKBP51 have been shown to regulate the status of tau in the brain 
but the structural basis for this interaction remains unresolved [45,50,68].  
NMR spectroscopy was used to investigate the interaction between tau, 
Hsp90, and FKBP51. Binding experiments were performed with 15N-labeled 
0N4R tau in the presence and absence of unlabeled Hsp90 and/or FKBP51. For 
titrations between tau and Hsp90 or tau and FKBP51, two samples of tau at the 
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same concentration were mixed with a stoichiometric excess (approximately 2:1 
see Figure 27B for SDS-PAGE gel image) of either Hsp90 or FKBP51. After 
HSQC spectra were collected, these two samples were combined and re-
concentrated to create a sample containing all three proteins as shown in the last 
lane of Figure 27B. An HSQC spectrum was then collected for tau in the 
presence of both Hsp90 and FKBP51. All three HSQC spectra were compared to 
the initial spectrum of free tau to look for chemical shifts or resonance intensity 
changes. Figures 22, 23 and 24 all show similar resonance intensity reduction 
profiles in the presence of Hsp90 and/or FKBP51. Specifically, residues that 
were mostly localized to the C-terminal assembly domain of tau experienced the 
largest resonance intensity reductions upon addition of Hsp90 and/or FKBP51. 
Sample Preparation of 0N4R tau 
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Figure 17. Purification workflow for tau. (A) Gel image for initial affinity Cobalt column (eluted 
at 3.0 mL/min) and (B) Post-cleavage affinity Cobalt column (eluted at 3.0 mL/min). 
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Figure 18. Post-cleave purification workflow for tau. (A) Post SEC (eluted at 0.5 mL/min) (B) 
Final Gel Image of FK1 (lane 2), tau (lane 3), and FK1 in the presence of tau (lane 4). 
 
  
 
 
 
 
Figure 19. Purification workflow for Hsp90. (A) Gel image for initial affinity Cobalt column 
(eluted at 3.0 mL/min). (B) (A) Post SEC (eluted at 0.35 mL/min). 
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2D NMR experiments with 15N-labeled 0N4R tau 
 
 
Figure 20. 1H15N HSQC for free 0N4R tau. This HSQC of 0N4R tau in the free state at a 
concentration of 0.1 mM will be used as a benchmark to measure any chemical shifts or intensity 
reductions for resonances upon addition of a potential binding partner.  
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Figure 21. Assigned HSQC of 0N4R tau. HSQC spectrum with labels corresponding to 
assigned residues on tau. 75% of residues were able to be assigned on the full length 383 
residue protein.  
Assigning 0N4R tau 
Resonance assignments for the amide nitrogens and protons of 0N4R tau 
were inferred from the previous assignment data for 0N4R tau and are listed in 
Appendix C [84]. Due to its disordered nature, relatively low sequence 
complexity, and the presence of multiple repeats, there is a high-degree of NMR 
signal overlap in the spectra. Tau’s lack of ordered structure also accounts for 
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the low amount of signal dispersion seen in the hydrogen dimension of the 
spectra. 
After collecting a spectrum for free tau and making resonance 
assignments another protein can be added to the sample and another HSQC can 
be collected to look for changes in chemical shifts or  intensity reductions. 
Figure 22. 1H15N HSQC for tau in presence of Hsp90. This is an overlay of the free tau HSQC 
spectrum (black resonances) from Figure 20 and a new HSQC spectrum (red resonances) taken 
of tau in the presence of Hsp90. Arrows indicate resonances in the C-terminal assembly domain 
on tau that become significantly less intense in the presence of Hsp90. 
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 Figure 23. 1H15N HSQC for tau in presence of FKBP51. This is an overlay of the free tau 
HSQC spectrum (black resonances) from Figure 20 and a new HSQC spectrum (blue 
resonances) taken of tau in the presence of FKBP51. Although the effect of FKBP51 is not as 
great as that of Hsp90 in tau binding, there is a similar intensity reduction profile in the 
hexapeptide regions of tau. 
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 Figure 24. 1H15N HSQC for tau in presence of Hsp90 and FKBP51. This is an overlay of the 
free tau HSQC spectrum (black resonances) from Figure 20 and a new HSQC spectrum (green 
resonances) taken of tau in the presence of Hsp90 and FKBP51.  
Analysis of resonance intensity ratios 
To identify individual residues from tau that are important for binding to 
FKBP51 and/or Hsp90, residue specific resonance intensities were measured for 
free tau and tau in the presence of Hsp90 and/or FKBP51 [77]. Due to the large 
molecular weight of the complex no chemical shifts are observable by NMR. 
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However, intensity ratios between the free and bound spectra can be directly 
measured and compared to determine which residues are experiencing 
significant changes in the presence a ligand. These intensity ratios are plotted for 
residues 270-441 in Figure 25 and for residues 10-40 in Figure 26. Intensity ratio 
plots for all assigned residues on tau can be found in Appendix D. Each plot is 
color coded such that red bars indicate intensity ratios between free tau and tau 
in the presence of Hsp90, blue bars indicate intensity ratios between free tau and 
tau in the presence of FKBP51, and green bars indicate intensity ratios between 
free tau and tau in the presence of both Hsp90 and FKBP51. The intensity ratios 
for tau in the presence of both Hsp90 and FKBP51 were divided by two to 
account for the doubling of tau concentration when the individual samples of tau 
plus Hsp90 and tau plus FKBP51 were mixed and re-concentrated. The pink line 
on each plot indicates one standard deviation below the mean and was 
calculated from the average intensity ratios for all assigned residues. 
Intensity ratios that are more than one standard deviation below the 
average value are probably involved in complex formation.  As seen in Figure 25, 
intensity ratios in this category are observed for residues V275 – K280 and V306 
– K311. These residues form the hydrophobic hexapeptide motifs mentioned 
above, and precede MT-binding repeat domains R2 and R3. These regions were 
previously identified as being important for binding to Hsp90 and are necessary 
for the formation of paired helical filaments that lead to the formation of 
neurotoxic aggregates [38,85,86].  
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Figures 25A and 25B demonstrate tau’s ability to bind independently to 
Hsp90 and FKBP51 and indicate the presence of overlapping binding sites in the 
hexapeptide regions of tau. Figure 25C shows what happens when all three 
proteins are mixed together, which should result in ternary complex formation. 
The intensity reductions observed in Figure 25C are not additive with respect to 
Figures 25A and 25B and it appears that the binding of Hsp90 dominates the 
effect seen in both hexapeptide motifs. This suggests that ternary complex 
formation is non-cooperative and the interaction between Hsp90 and tau is 
stronger than the interaction between FKBP51 and tau. It is important to note that 
the tau samples used in this study are unphosphorylated, while the form of tau 
that interacts in vivo with Hsp90 and FKBP51 is thought to be 
hyperphosphorylated [45].  
N-terminal residues in tau are involved in association with the co-
chaperone complex 
Intensity ratio plots in Figure 26 show that upon addition of Hsp90 and/or 
FKBP51, several residues near the N-terminus of tau also experience significant 
intensity reductions. However, intensity reductions in this region are not as large 
as those observed for the two hexapeptide motifs. Interestingly, the magnitude of 
the residue specific intensity reductions is greater for FKBP51. This can be seen 
by comparing Figures 26A and 26B. In Figure 26A, only one of the residues (E9) 
has an intensity ratio that is more than one standard deviation below the 
average. In contrast, a significant reduction is seen for the resonance intensities 
for residues 9, 10, 12-14, and 16 upon addition of FKBP51, as shown in Figure 
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Figure 25. Tau associates with Hsp90 and FKBP51 along C-terminal hexapeptide motifs.  (A) 
Intensity ratio plots for 15N-labeled tau in the presence of Hsp90. The two regions that experience the 
largest reductions are two hydrophobic hexapeptide regions, V275 – K280 and V306 – K311. (B) 
Intensity ratio plots for tau in the presence of FKBP51 show that tau has overlapping binding sites for 
Hsp90 and FKBP51. (C) The intensity ratios for ternary complex formation between tau and its 
molecular chaperone complex are additive when compared to tau bound to FKBP51 alone. Intensity 
ratios were determined by dividing the intensity of each resonance in the presence of Hsp90 and/or 
FKBP51 by the intensity of free tau. The pink line on each plot indicates one standard deviation below 
the mean and was calculated from the average intensity ratios for all assigned residues. 
26B. In Figure 26C, it appears this effect is amplified in the presence of both 
proteins. This suggests that the residues in the N-terminus of tau play some role 
in the formation of the Hsp90-FKBP51 complex either via self-interaction with the 
C-terminus or by making further contacts with the co-chaperone complex. This 
complements previous NMR and FRET data demonstrating tau’s ability to form a 
double hairpin or paperclip structure in which the N-terminus is transiently 
localized near the C-terminal assembly domain [24,87]. 
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 Figure 26. Global hairpin orientation of tau allows for further co-chaperone complex 
association via the N-terminus. (A) Intensity ratio plots for tau residues 1 – 40 show minimal 
intensity ratio reductions upon addition of Hsp90 to free tau. (B) Tau shows a stronger interaction 
in its N-terminus in the presence of FKBP51 as compared with tau in the presence of Hsp90. (C) 
However, upon conglomeration of all three proteins together, the largest reduction in resonance 
specific intensity ratios are observed. Intensity ratios were determined by dividing the intensity of 
each resonance in the presence of Hsp90 and/or FKBP51 by the intensity of free tau. 
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Line shape analysis of the most affected resonances in the hexapeptide 
regions 
In the presence of both Hsp90 and FKBP51, resonances in the two hexapeptide 
motifs show reduced signal intensity in the absence of line broadening in the hydrogen 
dimension. This is shown in Figure 27 for some of the most affected residues in each 
hexapeptide region, I278 and N279, and V309 and Y310. These figures show an overlay 
of projections along the hydrogen frequency dimension for all four spectra. Resonances 
that show reduced intensity in the absence of line broadening are probably undergoing 
chemical exchange with a bound conformation on a relatively slow timescale. A 
dissociation constant (Kd) in the low micromolar to nanomolar range can be inferred for 
residues that experience slow chemical exchange [76,77]. 
However, the behavior of the resonances shown in Figure 27B is not 
consistent with the presence of a two-fold excess of either Hsp90 or FKBP51. If 
the Kd is in the low micromolar range then a two-fold excess of either binding 
partner should saturate binding and lead to the complete disappearance of the 
free resonances. Since this did not occur we must assume that all of the Hsp90 
and FKBP51 that was titrated with tau was not competent for binding. This 
hypothesis was partially confirmed by performing dynamic light scattering (DLS) 
on concentrated samples of Hsp90 and FKBP51, which showed limited but 
significant evidence for aggregation of both proteins (Appendix A). When smaller 
systems undergo slow exchange, a resonance for the bound state may be 
observed. This is not the case for tau binding to either FKBP51 or Hsp90 
because the mass of the complex is beyond the range of detection for a standard 
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HSQC experiment. HSQC-TROSY experiments also failed to resolve bound 
resonances for the tau-FKBP51 complex or the tau-Hsp90 complex.  
Figure 27. Line shape analysis of most affected residues in hexapeptide regions. (A) 
Overlay of 1D projections along the hydrogen frequency dimension for all spectra. Line traces 
show the most affected residues in each of tau’s hydrophobic hexapeptide motifs – I278 and N279 
from the V275 – K280 hexapeptide, and V309 and Y310 from the V306 – K311 hexapeptide. Free 
tau is indicated by the black line. Red lines correspond to the tau-Hsp90 complex, blue lines 
correspond to the tau-FKBP51 complex, and green lines correspond to tau in the in a ternary 
complex with Hsp90 and FKBP51. These resonances experience reduced intensities in the 
absence of line broadening in the presence of Hsp90 and FKBP51. (B) 10% SDS-PAGE gel of 
final purified proteins used for NMR titrations. Gel lanes from left to right: (1) MW Protein Marker 
(Page Ruler Plus), (2) 0N4R tau, (3) 0N4R tau + Hsp90, (4) 0N4R tau + Hsp90, and (5) 0N4R tau 
+ Hsp90 + FKBP51.  
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Resin binding assay to confirm ternary complex formation 
 This section describes a binding assay that was developed based on the 
property that proteins possessing a 6X His-tag will bind to Cobalt resin. Since 
Hsp90 is the largest protein and likely forms the core of a co-chaperone complex 
capable of interacting with tau the 6X His-tag was used to immobilize  no more 
than 5 mg of Hsp90 to 500 µL of Co resin equilibrated in Co A1 binding buffer 
(See Methods for specifics buffer recipes). Subsequently, untagged proteins (tau 
and FKBP51) were applied to the column and incubated with Hsp90. The resin 
was washed to remove any non-specific bound proteins. Hsp90 was then eluted; 
presumably with tau and/or FKBP51 bound (a detailed protocol for the cobalt 
binding assay can be found in the methods section). Fractions collected were run 
against antibodies for Hsp90, tau and FKBP51. Those results are presented in 
Figures 28 and 29 below.   
 
Figure 28. Western blot results of tau and FKBP51 binding to 6X His-tagged Hsp90. E1, E2, 
and E3 represent the three elution fractions collected after the elution step. 5 µg of total protein 
was loaded in each well and run against antibodies for tau (HTau150), FKBP51 (51 M. Cox) and 
Hsp90α (90a ENZO) (Byrd Alzheimer’s Institute, Tampa, FL). Pre-mixed denotes protein samples 
that were pre-mixed for 30 minutes at 25°C prior to application to the mini column. Fractions with 
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+AMP-PNP indicates samples of Hsp90 that were incubated with AMP-PNP (a non-hydrolyzable 
version of ATP) for 30 minutes prior to application to the mini column.  
Figure 29. Western blot results of ternary 
complex formation for Hsp90, FKBP51 
and tau. E1, E2, and E3 represent the three 
elution fractions collected after the elution 
step. 5 µg of total protein was loaded in each 
well and run against antibodies for tau 
(HTau150), FKBP51 (51 M. Cox) and 
Hsp90α (90a ENZO) (Byrd Alzheimer’s 
Institute, Tampa, FL). Pre-mixed denotes 
protein samples that were pre-mixed for 30 minutes at 25°C prior to application to the mini 
column. Fractions with +AMP-PNP indicate samples of Hsp90 that were incubated with AMP-
PNP (a non-hydrolyzable version of ATP) for 30 minutes prior to application to the mini column. 
 Fractions analyzed by SDS-PAGE were of too low resolution to detect the 
quantities of proteins present in the fractions. Therefore, western blotting was 
performed on the same fractions probing with respective antibodies for Hsp90, 
tau, and FKBP51. The results demonstrate that tau and FKBP51 are able to 
associate with Hsp90 immobilized to Cobalt resin, both alone, and in the 
presence of one another. AMP-PNP was added in one round of experiments in 
an attempt to keep the Hsp90 dimer in an open conformation, however; it 
appears that when AMP-PNP is present there is a slight decrease in the 
association of tau and FKBP51 with Hsp90. This effect is further magnified when 
Hsp90 is incubated with AMP-PNP prior to application to the column, completely 
knocking out tau’s association with Hsp90 over the column, as shown in Figure 
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28. It is likely that in order for tau to associate with the co-chaperone complex, 
Hsp90 must first bind FKBP51, thereby altering its conformation and promoting 
the association of Hsp90 with tau. 
Model of the Hsp90-FKBP51 complex 
Based on the binding studies presented here and previous work on the 
interaction between tau, Hsp90, and FKBP51 [45,67,85,88,89], we are able to 
propose a structural model for the Hsp90-FKBP51 complex. It is known that the 
C-terminal TPR domain of FKBP51 will interact with the MEEVD sequence that is 
at the C-terminus of Hsp90. Using this minimal constraint as a starting point, the 
initial structures of FKBP51 and Hsp90 were taken from the RCSB Protein Data 
Bank, files 1KT0 and 2CG9, respectively [7,8,90]. From here, we manually 
created new PDB files from the previously existing files to place Hsp90 and 
FKBP51 in the context of one another in silico. Perhaps the most interesting 
observation between the crystal structures of these two proteins is the apparent 
complementary interface that exists between Hsp90 and FKBP51. This combined 
with the previous knowledge regarding the TPR domain of Hsp90 allowed us to 
manually orient the crystal structures in a way that the two interaction domains 
(TPR and MEEVD recognition site) would be within proximity to one another. 
This natural orientation also places the FK1 and FK2 domains of a single 
FKBP51 molecule near the bifurcated cleft formed by the Hsp90 dimer.  Given 
these considerations, an initial docking procedure using custom scripts (see 
Methods for full description simulation parameters) was performed using the 
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crystal structure of the closed form of human Hsp90 and the crystal structure of 
FKBP51.  
Figure 30. Structures of the Hsp90, FKBP51 and proposed FKBP51-Hsp90 complex. (A) 
Domain structure of human Hsp90 homodimer showing domain boundaries. Colors correspond to 
the domain boundaries for each of the main monomer subunits. (B) Structure of two FKBP51 
subunits aligned in 3D to fit Hsp90 homodimer at binding positions proposed in this study. FK1, 
FK2 and TPR domains are highlighted in red, green and blue, respectively. The PPIase binding 
site in FK1 domain is outlined with black circles. (C) Structure of the proposed Hsp90-FKBP51 
complex after 100ns of MD simulation. The figure was prepared using Pymol [57]. (Hsp90 PDB 
ID: 2CG9, FKBP51 PDB ID: 1KT0) 
44 
 
 
Using VMD for visualization, solvent accessible surfaces of both Hsp90 
and FKBP51 were used to define limiting boundaries for intermolecular steric 
clashes [91,92]. The crystal structure of the closed form of Hsp90 without the 
Sba1 co-chaperone proteins is presented in Figure 30A [8]. Figure 30A also 
highlights the domains of the Hsp90 homodimer with different colors. As 
mentioned previously, the two middle domain subunits of Hsp90 form a 
bifurcated cleft when Hsp90 is in the closed conformation. This surface topology, 
combined with knowledge that the C-terminal TPR domain of FKBP51 interacts 
with the C-terminal dimerization domain of Hsp90, suggests a possible 
orientation for FKBP51 relative to Hsp90 where two molecules of FKBP51 fit into 
the concentric groove that wraps around the two Hsp90 subunits and ends at the 
bifurcated cleft. In Figure 30B, two FKBP51 molecules are shown in an 
orientation where they fit into the groove on Hsp90. 
Monitoring the stability of the Hsp90 – FKBP51 complex 
To determine whether the model for the Hsp90-FKBP51 complex was 
plausible, a 100 ns molecular dynamics (MD) simulation was performed (see 
Methods). A snapshot of the final structure from the 100 ns MD trajectory is 
shown in Figure 30C. The PPIase active sites from both FK1 domains are facing 
towards the binding pocket formed by the bifurcated cleft on the middle domains 
of Hsp90. Both the FK2 and TPR domains remain aligned along the surface of 
Hsp90. The model shows that the binding sites of the TPR domains are in close 
proximity to the C-terminal dimerization domains and the intrinsically disordered 
linker of the C-terminal domain. The intrinsically disordered linker and the C-
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terminal MEEVD recognition site were not included in the model for two reasons. 
The first is the inherent uncertainty involved in modeling the disordered C-
terminal tail of Hsp90. The second reason was to determine whether the 
apparent complementary interface between Hsp90 and FKBP51 was sufficient to 
keep the complex together during the simulation. 
Figure 31. Plots of backbone RMSD and distances between geometric centers for the 
proposed Hsp90-FKBP51 complex model. Red and blue lines indicate individual monomers of 
Hsp90 or FKBP51. (A) Backbone RMSD of two main monomeric units of Hsp90 heterodimer. (B)  
Backbone RMSD of loop regions in PPIase binding sites for two FK1 domains. (C) Backbone 
RMSD for two FK1 domains excluding the loop regions in PPIase binding sites. (D) Backbone 
RMSD of two FK2 domains. (E) Backbone RMSD of two TPR domains. (F) Distance between 
geometric centers of FKBP51 and geometric center of Hsp90 measured for each of two bound 
FKBP51 subunits. 
Relevant distances were monitored over the course of the MD simulation 
to check the stability of the proposed model for the Hsp90-FKBP51 complex. 
46 
 
 
Some of these distances are plotted in Figure 31A. The root mean square 
difference (RMSD) in the position of the backbone atoms from the two subunits 
of Hsp90 is shown in Figure 31A. This figure shows that the RMSD of the 
backbone atoms for both Hsp90 subunits reaches an equilibrium value of less 
than 4 Å in the first 20 ns of the simulation. 
The FK1 domain of FKBP51 contains a disordered loop region between 
residues 113 and 126 that forms part of the PPIase active site (see black circle in 
Figure 30B). Figure 31B shows that this loop region has the highest backbone 
RMSD values when compared with the backbone RMSD of remaining residues in 
FK1, which are shown in Figure 31C. In the model proposed for the Hsp90-
FKBP51 complex, the loop region and the PPIase active site are facing the 
bifurcated cleft formed by the middle domain of Hsp90. The plot in Figure 31B 
demonstrates that the topology of the loops in both FK1 domains changes 
significantly with respect to the initial position in the PDB file. The backbone 
dynamics for these loops are stabilized at about 35 ns. Such behavior is driven 
by the interaction between these loops and the residues in the binding cleft of the 
middle domain of Hsp90, suggesting these loops are involved in forming a 
prominent interaction surface for the Hsp90-FKBP51 complex. The dynamics of 
the rest of the FK1 β-sheet backbone is quite rigid with similar backbone 
behavior observed in the FK2 and TPR domains, as shown in Figures 31D and 
31E, respectively.  
Figure 31F shows the distances between the geometric centers of each of 
FKBP51 subunit and the geometric center of the Hsp90 homodimer. The 
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distances for both FKBP51 subunits fluctuate by a couple of angstroms but are 
reasonably stable around a value of 46 Å after 25 ns. This highlights the fact that 
the FKBP51 subunits do not move apart from Hsp90 and emphasizes the 
mutually favorable interactions between FKBP51 and Hsp90. The RMSD and 
distance measurements presented in this section, along with the coordinates of 
the final structure from the 100 ns MD trajectory presented in Figure 30C, allows 
us to conclude that the model of the Hsp90-FKBP51 complex is reasonably 
stable.  
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CHAPTER FOUR: DISCUSSION 
The interaction between the FK1 domain and FK506 
The spectral analysis presented in chapter two presents an interesting 
case for the interaction between the FK1 domain of FKBP51 and tau. Firstly, it is 
curious that one of the most important residues in conferring PPIase activity, 
D68, experiences the most significant reduction in intensity upon addition of tau. 
In fact, studies on the PPIase activity in the FK1 regions have confirmed that D68 
mutants of FK1 experience partial or total loss of PPIase activity [6]. When 
Bracher et al. determined the crystal structure of FK1 in 2011, they determined 
that upon binding to FK506, residues Y57, F67, D68, F77, and I87 shift sideways 
allowing for a wider entrance to the binding site [6]. These residues line the rim of 
the conserved FK506 binding pocket.  
The interaction between the FK1 domain and tau  
Interestingly, in our intensity ratio plots for 15N-labeled FK1 in the presence 
of tau, residues Y57, D68, and I87 all experience significant intensity reductions 
either at or below one standard deviation from the mean (Y57 and F67 are 
unassigned). In our spectrum of 15N-labeled FK1 in the presence of tau, the 
residue that experienced that largest chemical shift was I87. Furthermore, 
Bracher et al. determined that the backbone amide of I87 was hydrogen bonded 
in all higher resolution structures published for the FK1 domain, indicating that 
bonding at the I87 amide might be crucial for an interaction to take place [6].  
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Based on this evidence we can conclude that D68, F77, and I87 may assist in 
orienting the tau protein so that it may interact with the active site.  
Upon examination of the crystal structure of FK1 bound to FK506 it is 
clear that several of the resonances that we see experience changes in the 
presence of tau also contribute to the largest intermolecular forces present in the 
binding pocket of the crystal structure. In particular hydrogen bonding between 
residues D68, I87, Q85 and Y113 contribute greatly to the strength of the 
interaction between FK1 and FK506 [6]. Our intensity ratio plots presented in 
Figure 15 also demonstrate that D68, I87, Q85 all experience significant intensity 
reductions in the presence of tau and we can reasonably conclude that these 
strong intermolecular forces are contributing to a weak interaction between FK1 
and tau. 
Regions that we showed to form strong beta-sheet structure experienced 
average changes in intensity. The strong beta-sheet topology surrounding a 
central helix on FK1 alone was also confirmed using HNCACB experiments. The 
residues in the HSQC spectra of FK1 that experienced the largest changes in 
intensity upon addition of tau also fall within regions that correspond to beta-
sheet structure.   
Tau associates with Hsp90 and FKBP51 using two C-terminal hexapeptide 
motifs 
Using NMR spectroscopy, MD simulations, and other biochemical 
techniques we have been able to further characterize tau’s interaction with 
Hsp90 and FKBP51 [45,67,88]. The NMR titrations presented in chapter three 
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between 15N-labeled tau, Hsp90, and FKBP51 provide the first structural 
assessment of the interaction and demonstrate that tau’s hexapeptide motifs 
form overlapping binding sites for Hsp90 and FKBP51. Previous evidence 
regarding the progression of an Hsp90 co-chaperone complex containing 
FKBP51 through the reaction cycle of ATP binding, hydrolysis, and release, 
showed that the presence of varying stoichiometries of co-chaperones can alter 
association of the complex with client proteins [88]. It is likely that the system 
described here comprised of Hsp90, FKBP51 and tau is missing other co-
chaperones that may be needed to alter Hsp90’s conformation and promote 
client association/dissociation. This assumption is supported by previous studies 
demonstrating that mixed co-chaperone complexes (e.g. those containing Hsp90, 
PPIases and other co-chaperones such as p23) are required for the full 
progression of the Hsp90 reaction cycle [67,88,89].  
It is normal for client and co-chaperone proteins to elicit competitive 
binding to various domains of Hsp90 [93]. It is difficult to infer the extent of 
competitive binding going on between Hsp90 and FKBP51 along the hexapeptide 
regions. This may be partly due to the homology between the two hexapeptide 
regions and the dynamic nature of full-length tau. Taking this into account, it is 
possible that tau could be bound to the co-chaperone complex in such a way that 
each hexapeptide region associates independently with either Hsp90 or FKBP51. 
The fact that Hsp90 and FKBP51 bind to overlapping sites on tau also suggests 
a possible model for ternary complex formation where Hsp90 localizes tau so 
that it can interact with the PPIase domain of FKBP51. Closer examination of 
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Figures 25A and 25B suggests that the interaction between Hsp90 and tau is 
probably stronger at residues V306 – K311 than that of tau with FKBP51 in the 
same region. This conclusion is based on the magnitude and extent of the 
resonance intensity reductions for residues V306 – K311 versus residues V275 – 
K280. This is consistent with a previous study showing that tau needs the 
hexapeptide V306 – K311 in order to interact with Hsp90 via co-
immunoprecipitation. This study was able to measure the association of tau’s 
hexapeptide regions with Hsp90 and concluded that Hsp90 can mediate a 
conformational change in the tau protein upon association [85]. Conversely, 
Figure 25B shows a stronger interaction between tau and FKBP51 in the 
hexapeptide V275 – K280. In terms of tau biology, these hexapeptides can form 
the highest amount of transient secondary structure in full length tau and are  
important for binding to Hsp90 [24,94]. The formation of transient beta-sheet 
structure is necessary for tau to aggregate and form paired helical filaments - the 
precursors to neurofibrillary tangle formation in the brain [24,94]. Mandlekow et 
al. has also shown that mutations in the hexapeptide regions promote tau 
aggregation [86]. 
Possible model of the Hsp90-FKBP51 co-chaperone complex 
Based on previous observations regarding the Hsp90-FKBP51 co-
chaperone complex and the NMR data presented here, a computational model 
simulating the Hsp90-FKBP51 complex was constructed [67,88,89]. MD 
simulations performed on this model demonstrate the complex is stable over a 
100 ns timescale and that there are no strong, unfavorable intermolecular forces 
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hindering the interaction. This is an important fact because it illustrates that it is 
at least possible for the complex to stay together. Although the TPR domain is 
important for the interaction between FKBP51 and Hsp90, it is not the only 
domain that facilitates the interaction. Previous co-immunoprecipitation studies 
have demonstrated that the FK domains (FK1 and FK2) must be present in order 
for FKBP51 to bind Hsp90 [66]. The computational model presented in Figure 30 
highlights the favorable interaction surface between the FK domains of FKBP51 
and Hsp90. 
In terms of the model presented in Figure 30, it is also important to note 
that the PPIase active site of the FK1 domain on FKBP51 is facing the bifurcated 
cleft formed by the Hsp90 homodimer, as shown in Figures 30B and 30C. 
Figure 32. Cartoon model of tau’s interaction with the Hsp90 – FKBP51 complex. HEX 1 and 
HEX 2 correspond to hexapeptide V275 – K280 and hexapeptide V306 – K311, respectively. 
Cartoon proposes a possible orientation where tau can interaction with FKBP51 and Hsp90 along 
HEX1 and HEX 2, respectively. 
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Looking more closely at the RMSD plots in Figure 31 it was noted that this loop 
region comprising residues 113-126 in the PPIase region on the FK1 domain, 
undergoes significant changes during the simulation upon interaction with the 
bifurcated cleft formed by the two middle domains of the Hsp90 dimer. We 
propose that this natural cleft may be a favorable site for tau to simultaneously 
bind Hsp90 and FKBP51, supporting a model for ternary complex formation 
where Hsp90 localizes tau so that it may interact with the PPIase domain of 
FKBP51. A cartoon model of this proposed interaction is presented in Figure 32. 
This has also been partially supported by our NMR data demonstrating that 
specific residues in the PPIase active site undergo changes in the presence of 
tau. 
Determining precisely how tau’s behavior is regulated in the brain will help 
us to further understand how protein-protein interactions and post-translational 
modifications along the way can lead to unregulated misfolding and aggregation 
of tau into tangles. Hsp90 is abundant in the brain and this study has succeeded 
in identifying specific regions on tau capable of interacting with Hsp90 and its co-
chaperone, FKBP51. Understanding how co-chaperones like FKBP51 interplay 
with Hsp90 is another piece of the tau regulation puzzle that is not quite clear but 
is ever emerging. Tau’s association with these complexes is important because 
the association of these proteins will ultimately regulate how and when tau is 
degraded. Unraveling the mechanism behind how alterations to tau’s degradation 
pathway affect normal protein homeostasis continues to be a major focal point of 
research studies on neurodegenerative disorders.  
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CHAPTER FIVE: MATERIALS AND METHODS 
Protein expression 
All proteins were expressed in the pET-28a vector system carrying genes 
for wild-type 0N4R tau (molecular mass 42,000.7 Da, 383 a.a.), Hsp90α 
(molecular mass 86,323.4 Da, 732 a.a.) and FKBP51 (molecular mass 52,212.2 
Da, 457 a.a ). Plasmids for full length 0N4R tau, Hsp90α, FKBP51 and were 
provided by Dr. Chad Dickey (Byrd Alzheimer’s Institute, Tampa, FL). Original 
vectors were modified via mutagenesis to include a TEV protease site prior to the 
N-terminus of the tau gene and a PreScission protease site prior to the N-
terminus of the FKBP51 gene. FK1 (15,168 Da, 138 a.a.) constructs were 
obtained from GeneArt (Invitrogen, Grand Island, NY) in a pUC vector and 
subsequently cloned into a pET-28a vector including a 6XHis tag. All plasmids 
were transformed into Escherichia coli strain BL21 (DE3).  All tau, FKBP51, and 
FK1 protein expression was performed at 37°C in M9 minimal media which 
allows for efficient metabolic incorporation of isotope labels such as 15N and 13C 
by using 15NH4Cl and 13C D-Glucose. Hsp90α expression was also done in M9 
minimal media, however; induction was carried out at 18°C for 20hrs to achieve 
optimal expression levels. For all proteins, expression was induced at OD 0.8 by 
addition of 1mM isopropyl-β-D-thiogalactopyranoside (IPTG) to 2L culture flasks, 
grown for 4 - 20 hours, pelleted via centrifugation at 8000 rpm for 15 min. at 4°C 
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and stored at -80°C. The recipe for M9 media can be found in the Methods 
section under the subheading ‘Buffer Recipes’. 
Protein purification 
Cell pellets were thawed and re-suspended in a PBS buffer containing 
10mM Imidazole, 100µM PMSF and P2174 (10X)  protease inhibitor cocktail from 
Sigma Aldrich. Cells were lysed via French Press at ≥ 20,000 psi. The lysate was 
separated via centrifugation at 18,000 rpm for 1 hour at 4°C. The clarified lysate 
was loaded onto a column containing HisPur™ cobalt resin (Thermo Scientific, 
West Palm Beach, FL). Prior to purification, the resin was equilibrated with 50 
mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, 0.02% NaN3, 4 mM DTT, pH 7.4 
and eluted with 150 mM Imidazole. The Histidine tag was cleaved using TEV or 
HRV3C proteases and separated from the untagged protein using a column 
containing  HisPur™ cobalt resin. Cleaved proteins were then dialyzed into a gel 
filtration buffer (50 mM NaH2PO4, 300 mM NaCl, 1 mM EDTA, 0.02% NaN3, pH 
7.0) and loaded onto a HiLoad 16/60 Superdex 75 prep grade column 
(Pharmacia, 17 1068-01).  All proteins were eluted with a flow rate of 0.35 or 1.0 
mL/min, pooled and dialyzed into an appropriate buffer for NMR analysis, and 
finally concentrated to 2-15 mg/mL. All proteins were confirmed to be ≥90% pure 
by Coomassie stained SDS-PAGE. The workflow for the purification of all 
proteins can be found in the Sample Preparation section of Chapters 2 and 3. 
Recipes for all media and buffers can be found in the Methods section under the 
subheading ‘Buffer Recipes’. 
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Determining protein concentration 
Proteins were concentrated using Milipore (Billerica, MA) centrifugal filter 
units with a 3,500 MWCO, spun at 3300 RCF. All protein concentrations were 
determined using a Nanodrop ND-1000 requiring 2µL of sample to conduct the 
assay. Absorbances were taken at 280 nm and are based on the presence of 
tryptophan, tyrosine and cysteine residues. Extinction coefficients were 
calculated using publically available software ProtParam from Expasy and are 
listed below for all proteins.  
Protein Reference Chart 
Protein MW w/o tag 
(KDa) 
E.C. 
(M/cm) 
Length 
(a.a.) 
# of C 
Residues 
pI 
tau 40000.7 7450 383 2 9.46 
Hsp90α 84659.7 59250 732 7 4.94 
Hsp90β 83264.2 57760 724 6 4.96 
FKBP51 51212 40340 457 9 5.71 
FK1 15168 11460 138 2 6.83 
      
 
Figure 33. Protein reference chart. MW indicates the molecular weight in KDa of each protein 
of interest. E.C. stands for extinction coefficient, which is used to determine the final 
concentration of the protein. # of C residues denotes the numbers of cysteine residues present 
and pI denotes the isoelectric point of each protein.  
NMR data acquisition 
Experimental parameters 
NMR experiments on tau were carried out at 298 K on a Varian VNMRS 800 
MHz spectrometer equipped with a triple resonance pulse field Z-axis gradient 
cold probe. Resonance assignments for 0N4R tau were inferred using previous 
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assignments [24,84]. To make the amide 1H and 15N resonance assignments, 
sensitivity enhanced 1H-15N HSQC were performed on the uniformly 15N-labeled 
tau samples in 90%H2O/10% D2O, PBS buffer with 4mM DTT at a pH 6.0. For 
the HSQC experiments, data were acquired in 1H and 15N dimensions using 
2100.0 (t2)  9615.3846 (t1) Hz sweep widths, and 1024 (t2) 128 (t1) complex data 
points. HNCACB experiment data were acquired in 1H, 13C and 15N dimensions 
using 8012.8 (t3) x 12000 (t2) x 2000 (t1) Hz sweep widths, and 1024 (t3) x 128 
(t2) x 32 (t1) complex data points.  All NMR spectra were processed with 
nmrPipe and analyzed using nmrView [95]. The 1H carrier frequency was set on 
the water peak, and 4.753 ppm was used as the reference frequency. 
HSQC and HNCACB experiments 
The heteronuclear single quantum coherence (HSQC) experiment is a two 
dimensional heteronuclear shift correlation experiments that can monitor how a 
spin is transferred between a proton and another bonded atom. In this case we 
are exploiting the fact that each residue of a protein (with the exception of 
proline) has an amide proton attached to nitrogen in the peptide bond. This 
experiment is designed such that a spin is transferred from the amide proton to 
the nitrogen and back again to yield a resonance for each non-proline residue of 
the protein. These experiments were primarily used in order to determine the 
change in chemical shifts and/or intensity changes for those residues involved in 
binding. 
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While the HSQC is a high resolution two dimensional NMR experiment 
correlating the 1H and 15N atoms, HNCACB experiments are three dimensional 
NMR experiments that can be used to assign all residues along the backbone of 
a protein of interest. The HNCACB requires the protein to have both magnetically 
labeled N, and C, and the experiments are designed such that the spin is 
transferred from the amide proton through the covalent bonds to the N, Cα and 
Cβ atoms and back, yielding a signal that has resonances in the corresponding 
frequencies.  This allows a spectra to be generated in three dimensions with the 
1H, 15N, and 13C making up the x, z, and y axis respectively. For the HNCACB 
there is also a weaker resonance coming from the previous residues’ C atoms. 
This allows for the correlation of multiple spin system, generating a more high 
definition picture of the backbone of the protein.  
Cobalt binding assay 
Binding experiments were performed on cobalt His-Pur Resin (Thermo 
Scientific, West Palm Beach, FL) using mini 1mL columns obtained from Bio-Rad 
(Hercules, CA). 500µL of a 50% resin slurry was spun down at 700 x g for 2 
minutes and the supernatant was removed. Cobalt resin was washed with three 
bed volumes (750µL) of cobalt A1 Buffer. 500 µL of a His-tagged protein (in Co 
A1) was applied to the resin and incubated at room temperature with gentle 
agitation for 30 minutes. Resin with bound protein was washed with three bed 
volumes of Co A1 to wash out any unbound sample. On the second wash the 
supernatant was removed and a 15 µL sample was taken for SDS-PAGE 
analysis. 1mL of non-tagged proteins were applied to the resin with bound 
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Hsp90, respectively. Tubes were incubated at room temperature with gentle 
agitation for 30 minutes. Resin was then washed with three bed volumes of Co 
A1. Samples of the supernatant and the resin were taken following centrifugation 
after the third wash. The His-tagged protein was eluted with 150mM Imidazole. 
15µL samples were taken from the supernatant following elution. All samples 
were mixed with 15 µL of 2x Lamelli Buffer and run on a 10% SDS-PAGE gel at 
200V for 50 minutes. 
Molecular dynamics simulation  
All molecular dynamics simulations were performed over 100 ns using GROMACS 4.5 
[96-98] with the AMBER99SB force field [99] in a periodic dodecahedron box with TIP3P 
water [100]. The nearest distance from the box edge was set to 1.2 nm. Ions were added 
to a concentration of 0.15 M to neutralize the system. 5000 steps of a steepest descent 
algorithm was used for energy minimization, with a tolerance of 1000 kJ/(mol/nm). After 
energy minimization, a 700 ps position restrained molecular dynamics simulation at 
constant volume (NVT) was performed to equilibrate the water molecules around the 
complex and stabilize temperature. The temperature (300 K) of the system was 
controlled with the Berendsen algorithm [101]. Afterward, an unrestrained molecular 
dynamics simulation of the system was carried out for 50 ns at constant pressure, and 
temperature (NPT). The temperature (300 K)  and pressure (1 atm) of the simulation 
was controlled using the Nose-Hoover thermostat [102,103] and Parrinello-Rahman 
barostat, respectively [104]. The Lincs algorithm [105] was used to constrain all bonds to 
their equilibrium lengths, allowing a time step of 2 fs. Particle Mesh Ewald (PME) method 
[106] was applied for electrostatics with a real space cutoff of 0.8 nm, a grid spacing of 
0.12 nm and cubic spline interpolation. The cutoff for non-bonded Van der Waals 
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interactions was set to 0.8 nm. A detailed experimental rationale is given in the Results 
and Discussion section under the subheading Model of the Hsp90-FKBP51 Complex. 
Subcloning of GeneArt constructs 
- Worktable for restriction digest of plasmid obtained from GeneArt to 
recover insert of interest or open new vector for cut and paste 
- Table 1. Worktable for restriction digestions. 
Reagent Volume 
H20 6 µL 
NEB Buffer 2 µL 
GeneArt Plasmid/Vector 10 µL 
XhoI 1 µL 
EcoRI 1 µL 
Total: 20µL 
 
- Tubes gently mixed and incubated for 16h at 37⁰C at 250rpm.  
- The digested plasmid sample is run on an agarose gel in order to separate 
the vector from the insert of interest. A gel extraction procedure is then 
performed using a OIAquick Gel Extraction Kit (Oiagen, Germantown, MD) 
in order to remove and purify the insert from the agarose gel.  
Ligation of construct into vector of interest 
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- Once the insert of interest has been separated and purified from the pUC 
vector and the vector of interest (pET28a) has been digested, the two can 
be ligated together. 
- Table 2. Worktable for ligation reactions. 
Reagent Mix 1 Mix 2 
10X T4 buffer 2 µL 2 µL 
Vector DNA 1 µL 2 µL 
Insert 10 µL 15 µL 
H2O 6 µL 0 µL 
T4 ligase 1 µL 1 µL 
Total: 20 µL 20 µL 
 
- Prepare two different reaction tubes according to the chart above and 
incubate overnight at 16⁰C for 16h. 
Transformation of newly ligated constructs 
- Transform 2.5 µl of each ligation reaction into NEB5α cells. Plate the 
entire 100 µl transformation reaction onto LB media with kanamycin. 
Incubate overnight at 37⁰C for 18 to 22 hours. 
- Inoculate 6ml NZY broth + kanamycin/ ampicillin with individual colonies 
from overnight plates. Incubate in shaker incubator at 37⁰C for 16h. 
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- Extract plasmid using Qiagen Plasmid Miniprep Kit (Qiagen, Germantown, 
MD). Elute in 30 µl EB buffer. Estimate plasmid concentration using the 
Nanodrop Spectrophotometer. Send 15 µl to Operon (Eurofins MWG, 
Huntsville, AL) for sequencing.  
Buffer Recipes 
Preparation of M9 Minimal Media (2L): 
Stock Solutions for M9 
- 10X M9 Salts (1L) 
  Na2HPO4 60g 
  KH2PO4 30g 
  NaCl  5g 
   
- 1M MgSO4 Filter sterilized 
- 20% Dextrose Filter sterilized 
- 50mM CaCl2 Filter sterilize 
- 0.01 M FeCl3  
- 5mg/ml Vitamin B1  
M9 Minimal Media: 
- 200mL of 10x M9 salts 
- 4mL 1M MgSO4 
- 20mL of 20% D-Glucose 
- 4mL of 50mM CaCl2 
- 2mL 0.01M FeCl3 
- 400uL of 5mg/mL Vitamin B1 
- pH to 7.3-7.5  
- QS to 2L with ddH2O 
Preparation of Cobalt Column Buffers (1L): 
Co A1 Buffer (Lysis/Binding) 
- 50mM NaH2PO4   
- 300mM NaCl      
- 10mM Imidazole 
- 0.02% NaN3    
- pH to 7.40  
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Co A2 Buffer (Wash) 
- 50mM NaH2PO4   
- 300mM NaCl      
- 20mM Imidazole 
- 0.02% NaN3    
- pH to 7.40 
Co B Buffer (Elution) 
- 50mM NaH2PO4   
- 300mM NaCl      
- 150mM Imidazole 
- 0.02% NaN3    
- pH to 7.40 
 
Preparation of Gel Filtration, NMR (1L): 
Gel Filtration Buffer: 
- 50mM NaH2PO4 
- 300mM NaCl 
- 1mM EDTA 
- 4mM DTT   
- 0.02% NaN3 
- pH 7.00  
NMR Buffer: 
- 25mM NaH2PO4 
- 100mM NaCl 
- 1mM EDTA 
- 4mM DTT   
- 0.02% NaN3  
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APPENDICES 
APPENDIX A: Dynamic Light Scattering Results 
 
 
Figure A1. Dynamic Light Scattering Results. Top panel shows DLS of  
Hsp90 at 0.250 mM and bottom panel shows DLS of FKBP51 at 0.01 mM. 
Dynamic Light Scattering 
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APPENDIX B: NMR Chemical Shift and Assignment Data for FK1 
Table A1. Peak List and Chemical Shifts for 13C15N-labeled FK1 
# AA Cα Cβ NH N 
1 M 55.56741 33.16497   
2 T 61.69434 69.7916 8.23567 115.78858 
3 T 61.65497 69.82626 8.19406 115.96677 
4 D 54.38185 41.24771 8.35551 122.8907 
5 E 57.21672 30.05092 8.45057 122.28542 
6 G 45.40805  8.41964 109.25886 
7 A 52.58298 19.25962 7.9778 123.66524 
8 K 56.24578 32.98483 8.18787 120.23803 
9 N 53.39845 38.94128   
10 N 53.39845 38.94128 8.38879 119.45626 
11 E 56.61387 30.31481 8.29437 120.92284 
12 E 56.3829 30.35683 8.32291 121.82581 
13 S 55.89612 63.30598 8.39443 117.89005 
14 P 63.3929 32.17795   
15 T 61.85286 69.6507 8.16758 114.37888 
16 A 52.5358 19.46785 8.22961 126.7705 
17 T 61.85162 69.69791 8.05158 113.11143 
18 V 62.13806 32.87038 8.15771 122.93578 
19 A 52.51447 19.36623 8.35119 127.93896 
20 E 56.61197 30.26074 8.34487 120.50468 
21 Q 55.9259 29.72264 8.41733 121.23191 
22 G 45.53946  8.97852 111.91369 
23 E 54.99217 31.74515 8.89347 122.78767 
24 D 53.69767 39.86588 8.85458 125.04137 
25 I 60.91776 37.459 7.74419 120.21203 
26 T 62.50499 70.55043 8.52325 114.17397 
27 S 60.52031 62.75695 8.80448 118.17658 
28 K 56.96548 32.76416 8.0847 119.48365 
29 K 55.10236 32.55208 7.79543 116.817 
30 D 52.12553 41.31226 7.69835 117.72147 
31 R 57.85491 26.72038   
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Continuation of Table A1. Peak List and Chemical Shifts for 13C15N-labeled 
FK1 
      
32 G 46.9373  8.87738 105.18037 
33 V 62.18152 34.68372 6.2448 115.92564 
34 L 52.78006 46.1561 8.4052 125.36332 
35 K 54.91516 38.98117 9.12545 121.85793 
36 I 59.85765 42.54462 8.9518 125.86557 
37 V 64.46331 31.84687 9.10519 128.20941 
38 K 54.74797 31.90417 8.74224 128.57001 
39 R 55.66148 34.14418 8.10706 121.70131 
40 V 62.91138 32.27299 8.49361 126.61909 
41 G 44.02576  9.72428 112.99355 
42 N 52.85679 41.23154 8.89751 117.45747 
43 G 45.40805  8.41274 109.41523 
44 E 56.02808 29.46675 8.2779 119.87441 
45 E 55.65244 32.84181 8.39538 121.5531 
46 T 61.90369 69.72392 8.13522 114.31333 
47 P 62.2468 31.5305   
48 M 52.80655 35.19386 8.72412 120.7681 
49 I 63.52189 37.10711 8.07589 120.19561 
50 G 44.77468  9.33099 116.72478 
51 D 55.21166 40.4242 8.42825 123.59737 
52 K 55.89235 32.71907 8.8605 122.2594 
53 V 59.54971 33.11845 8.63954 119.23489 
54 Y 55.81822 39.96127 8.05612 120.81375 
55 V 58.32961 35.63976 9.52272 114.98199 
56 H 54.73818 35.31664 8.7199 119.20776 
57 Y      
58 K 56.2489586 36.5998497 8.95236015 119.182861 
59 G 45.5151405  8.98554039 111.861977 
60 K 54.8755188 37.53965 9.45153999 124.764107 
61 L 54.4146194 42.1315689 8.75926018 120.088226 
62 S     
63 N 52.59135 37.42501 7.46643 117.26268 
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Continuation of Table A1. Peak List and Chemical Shifts for 13C15N-labeled 
FK1 
64 G 45.02737  8.22791 107.90089 
65 K 56.36945 31.47277 8.38256 116.82005 
66 K 57.56284 31.01814 8.26131 119.27572 
67 F 56.52079 41.14852   
68 D 54.60372 44.47718 6.96678 118.6972 
69 S 56.79387 65.20155 8.34758 116.93421 
70 S 58.18072 63.72445 8.34475 116.96164 
71 H 55.7593 29.46879 8.67103 121.01128 
72 D     
73 R     
74 N     
75 E     
76 P 62.54616 32.24281   
77 F 57.77422 41.53698 9.30612 124.91258 
78 V 59.28852 34.07311 7.37516 127.25642 
79 F 55.50563 40.69008 8.13847 120.83193 
80 S 56.62948 63.13042 8.34774 115.3137 
81 L 56.59764 42.27339 8.90211 129.84496 
82 G 46.86366  9.20708 115.22227 
83 K 53.85117 32.762 7.77116 117.24957 
84 G 46.6798  8.84247 111.8952 
85 Q 56.87688 29.40343 9.23372 118.69217 
86 V 57.40725 35.85967 6.82778 109.06683 
87 I 61.7086 38.40494 7.07582 111.99664 
88 K 59.6177 33.05133 8.88483 124.69365 
89 A 55.23829 20.91516 8.8987 114.33505 
90 W 59.56803 29.08845 7.61381 115.31712 
91 D 57.80404 40.48963 7.06249 121.91173 
92 I 63.95063 39.48651 8.12443 115.49307 
93 G 47.05078 39.42239 8.48574 105.62881 
94 V 66.45195 30.13501 9.3947 124.66789 
95 A 53.96693 18.97215 6.33649 116.43687 
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Continuation of Table A1. Peak List and Chemical Shifts for 13C15N-labeled 
FK1 
96 T 61.54445 71.13624 7.10846 103.61083 
97 M 56.57845 36.2843 7.34722 123.56704 
98 K 54.05819 35.12584 7.13474 115.88678 
99 K 60.25718 30.50966 9.27812 121.01232 
100 G 45.24708 0 9.03284 113.46843 
101 E 55.89198 33.88329 8.41961 124.62167 
102 I 60.23503 40.25872 8.53228 121.24797 
103 C 54.70619 32.6102 9.71229 123.88232 
104 H 52.70061 34.74151 9.1962 120.10197 
105 L 52.52476 47.22847 9.09416 120.89021 
106 L 53.87385 46.24059 9.07495 125.77542 
107 C 55.61449 31.3467 9.56105 124.84819 
108 K     
109 P 65.60266 31.17132   
110 E 59.57081 28.35925 9.62913 119.00423 
111 Y 58.11855 39.41819 8.06457 117.16912 
112 A 51.58308 19.36328 7.90091 125.37965 
113 Y     
114 G     
115 S     
116 A 54.3014984 19.1370907 8.67115021 124.808411 
117 G  44.31707   
118 S 61.2134209 44.2375908 8.60358047 115.618294 
119 L     
120 P     
121 K     
122 I     
123 P 61.75363 33.20723   
124 S 59.59579 63.93246 8.3858 113.33275 
125 N 54.61055 37.22884 8.16482 120.9895 
126 A 52.52291 20.55093 7.94286 121.68728 
127 T 63.11993 69.19085 8.60747 122.54504 
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Continuation of Table A1. Peak List and Chemical Shifts for 13C15N-labeled 
FK1 
128 L 53.34252 46.44555 8.735 125.40909 
129 F 55.4854 42.31112 8.76384 122.74904 
130 F 55.94334 44.26237 8.85945 121.27012 
131 E 54.88714 32.75718 8.6774 121.46977 
132 I 60.20597 41.24478 8.98912 125.79225 
133 E 53.24091 33.60151 9.32124 128.84044 
134 L 54.34349 40.79915 8.45705 127.92609 
135 L 57.07132 42.37034 9.1376 129.53587 
136 D 52.82453 42.98111 7.88522 110.93533 
137 F 56.57823 42.06094 8.371 115.15088 
138 K 57.5233 35.42819 9.11816 124.59063 
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Table A2. Secondary Cα Chemical Shift Values  
# AA FK1 Cα Shift  Values (ppm) 
Standard Cα 
 Shift Values (ppm) 
Δ Cα 
(ppm) 
1 M 55.56741 55.75 -0.18259 
2 T 61.69434 61.87 -0.17566 
3 T 61.65497 62.12 -0.46503 
4 D 54.38185 54.14 0.24185 
5 E 57.21672 56.93 0.28672 
6 G 45.40805 45.26 0.14805 
7 A 52.58298 52.64 -0.05702 
8 K 56.24578 56.67 -0.42422 
9 N 53.39845 53.25 0.14845 
10 N 53.39845 53.46 -0.06155 
11 E 56.61387 56.86 -0.24613 
12 E 56.3829 56.46 -0.0771 
13 S 55.89612 56.75 -0.85388 
14 P 63.3929 63.78 -0.3871 
15 T 61.85286 61.84 0.01286 
16 A 52.5358 52.85 -0.3142 
17 T 61.85162 61.83 0.02162 
18 V 62.13806 62.55 -0.41194 
19 A 52.51447 52.68 -0.16553 
20 E 56.61197 56.71 -0.09803 
21 Q 55.9259 56.25 -0.3241 
22 G 45.53946 45.34 0.19946 
23 E 54.99217 56.64 -1.64783 
24 D 53.69767 53.94 -0.24233 
25 I 60.91776 61.82 -0.90224 
26 T 62.50499 61.89 0.61499 
27 S 60.52031 58.72 1.80031 
28 K 56.96548 56.69 0.27548 
29 K 55.10236 56.68 -1.57764 
30 D 52.12553 54.03 -1.90447 
31 R 57.85491 56.7 1.15491 
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Continuation of Table A2. Secondary Cα Chemical Shift Values 
 
32 G 46.9373 45.16 1.7773 
33 V 62.18152 62.51 -0.32848 
34 L 52.78006 55.3 -2.51994 
35 K 54.91516 56.47 -1.55484 
36 I 59.85765 61.38 -1.52235 
37 V 64.46331 62.5 1.96331 
38 K 54.74797 56.56 -1.81203 
39 R 55.66148 56.28 -0.61852 
40 V 62.91138 62.55 0.36138 
41 G 44.02576 45.37 -1.34424 
42 N 52.85679 53.3 -0.44321 
43 G 45.40805 45.54 -0.13195 
44 E 56.02808 56.62 -0.59192 
45 E 55.65244 56.49 -0.83756 
46 T 61.90369 60.06 1.84369 
47 P 62.2468 63.86 -1.6132 
48 M 52.80655 55.62 -2.81345 
49 I 63.52189 61.55 1.97189 
50 G 44.77468 45.39 -0.61532 
51 D 55.21166 53.94 1.27166 
52 K 55.89235 56.67 -0.77765 
53 V 59.54971 62.28 -2.73029 
54 Y 55.81822 58.04 -2.22178 
55 V 58.32961 62.51 -4.18039 
56 H 54.73818 55.14 -0.40182 
57 Y  58.22  
58 K 56.24895859 56.76 -0.5110414 
59 G 45.51514053 45.25 0.2651405 
60 K 54.8755188 56.62 -1.7444812 
61 L 54.41461945 55.34 -0.9253806 
62 S  58.72  
63 N 52.59135 53.44 -0.84865 
64 G 45.02737 45.51 -0.48263 
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Continuation of Table A2. Secondary Cα Chemical Shift Values 
 
65 K 56.36945 56.53 -0.16055 
66 K 57.56284 56.42 1.14284 
67 F 56.52079 58.1 -1.57921 
68 D 54.60372 54.1 0.50372 
69 S 56.79387 58.83 -2.03613 
70 S 58.18072 58.7 -0.51928 
71 H 55.7593 55.53 0.2293 
72 D  53.99  
73 R  56.72  
74 N  52.98  
75 E  54.88  
76 P 62.54616 63.46 -0.91384 
77 F 57.77422 57.85 -0.07578 
78 V 59.28852 62.47 -3.18148 
79 F 55.50563 58 -2.49437 
80 S 56.62948 58.67 -2.04052 
81 L 56.59764 55.63 0.96764 
82 G 46.86366 45.32 1.54366 
83 K 53.85117 56.7 -2.84883 
84 G 46.6798 45.25 1.4298 
85 Q 56.87688 55.94 0.93688 
86 V 57.40725 62.43 -5.02275 
87 I 61.7086 61.46 0.2486 
88 K 59.6177 56.51 3.1077 
89 A 55.23829 52.6 2.63829 
90 W 59.56803 57.61 1.95803 
91 D 57.80404 53.94 3.86404 
92 I 63.95063 61.7 2.25063 
93 G 47.05078 45.15 1.90078 
94 V 66.45195 62.44 4.01195 
95 A 53.96693 52.74 1.22693 
96 T 61.54445 62.16 -0.61555 
97 M 56.57845 55.81 0.76845 
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Continuation of Table A2. Secondary Cα Chemical Shift Values 
 
98 K 54.05819 56.53 -2.47181 
99 K 60.25718 56.68 3.57718 
100 G 45.24708 45.25 -0.00292 
101 E 55.89198 56.49 -0.59802 
102 I 60.23503 61.53 -1.29497 
103 C 54.70619 58.5 -3.79381 
104 H 52.70061 55.41 -2.70939 
105 L 52.52476 55.38 -2.85524 
106 L 53.87385 55.46 -1.58615 
107 C 55.61449 58.32 -2.70551 
108 K  54.81  
109 P 65.60266 63.52 2.08266 
110 E 59.57081 56.5 3.07081 
111 Y 58.11855 58.15 -0.03145 
112 A 51.58308 52.65 -1.06692 
113 Y  58.35  
114 G 46.39273 45.37 1.02273 
115 S  58.52  
116 A 54.3014984 52.93 1.3714984 
117 G  45.37  
118 S 61.2134209 58.39 2.8234209 
119 L  53.62  
120 P  63.55  
121 K  56.32  
122 I  59.62  
123 P 61.75363 63.57 -1.81637 
124 S 59.59579 58.69 0.90579 
125 N 54.61055 53.29 1.32055 
126 A 52.52291 52.98 -0.45709 
127 T 63.11993 61.9 1.21993 
128 L 53.34252 55.33 -1.98748 
129 F 55.4854 57.89 -2.4046 
130 F 55.94334 58.03 -2.08666 
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Continuation of Table A2. Secondary Cα Chemical Shift Values 
 
131 E 54.88714 56.56 -1.67286 
132 I 60.20597 61.57 -1.36403 
133 E 53.24091 56.59 -3.34909 
134 L 54.34349 55.44 -1.09651 
135 L 57.07132 55.47 1.60132 
136 D 52.82453 53.91 -1.08547 
137 F 56.57823 58.26 -1.68177 
138 K 57.5233 56.75 0.7733 
139 G 45.38262 45.25 0.13262 
140 K 58.0316 57.89 0.1416 
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Table A3. Intensity Ratios for free FK1 vs. FK1 in the presence of tau  
AA 
FK1  
Intensity 
FK1+tau 
Intensity 
FK1+tau  
Intensity Ratio 
2T 2.0815506 1.571737885 0.755080317 
3T 2.2140162 1.856165528 0.838370347 
4D 2.29990005 1.817488194 0.790246598 
5E 0.23636067 0.163030565 0.689753356 
6G 2.64907932 2.136030912 0.80632954 
7A 3.46071339 2.756175041 0.796418175 
8K 2.29751134 1.922115684 0.836607703 
9N 1.69227874 1.360085607 0.803700698 
10N 1.63955057 1.3586905 0.828696917 
11E 2.03474689 1.744387507 0.85729951 
12E 2.29641366 1.748647332 0.76146879 
13S 1.94202912 1.545189261 0.795657103 
15T 0.80534911 0.587622881 0.729649878 
16A 0.94885361 0.632546067 0.666642419 
17T 1.20860803 0.953160942 0.788643561 
18V 0.68527681 0.513116896 0.748773184 
19A 0.84457272 0.600877225 0.711457059 
20E 1.00974154 0.712035418 0.705166011 
21Q 0.50692153 0.424958646 0.838312483 
22G 0.66873491 0.474486232 0.709528134 
23E 0.58808452 0.412037343 0.70064307 
24D 0.71550715 0.522549987 0.730321125 
25I 0.39698616 0.275571555 0.694159104 
26T 0.61310589 0.445648968 0.726871122 
27S 0.17445417 0.151075348 0.86598876 
28K 0.47302878 0.367112964 0.776090125 
29K 0.3725163 0.23927182 0.642312341 
30D 0.50862378 0.368313879 0.724138143 
31R 0.52281934 0.340140849 0.650589646 
32G 0.62486017 0.44931066 0.719057933 
33V 0.93226594 0.664797068 0.713098099 
34L 0.54730803 0.384274095 0.70211668 
35K 0.47936392 0.326564342 0.681245144 
36I 0.48633564 0.36034897 0.740947082 
37V 0.57292295 0.492393255 0.859440627 
38K 0.26631987 0.184845909 0.694074794 
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Continuation of Table A3. Intensity Ratios for free FK1 vs. FK1 in the 
presence of tau  
39R 0.55344117 0.382978946 0.691995769 
40V 0.7088778 0.519112289 0.732301516 
41G 0.35309327 0.262744933 0.744123319 
42N 0.80480903 0.599369824 0.744735457 
43G 1.41017783 1.063755393 0.754341313 
44E 0.8486591 0.626165867 0.737829675 
45E 1.44434094 1.153669477 0.798751487 
46T 0.93181455 0.6712479 0.720366406 
48M 0.60378766 0.464031279 0.768533889 
49I 0.89523274 0.745827019 0.833109635 
50G 0.45728692 0.30643028 0.670105057 
51D 0.75708067 0.507020235 0.669704369 
52K 0.61306554 0.455993474 0.743792373 
53V 0.47642744 0.329911619 0.692469817 
54Y 0.41486186 0.356076956 0.858302466 
55V 0.54645205 0.407720923 0.746123886 
56H 0.36993194 0.24526237 0.662993231 
58K 0.44404504 0.290670931 0.654597861 
59G 0.39633289 0.304258168 0.767683368 
60K 0.22281384 0.156543091 0.702573447 
61L 0.39752051 0.264596671 0.665617654 
62S 0.35685569 0.276965499 0.776127455 
63N 0.54194355 0.41367808 0.763323191 
64G 0.57526714 0.443878949 0.771604913 
65K 0.86597055 0.677552223 0.782419473 
68D 0.16404828 0.090796247 0.553472702 
69S 0.55121118 0.38378647 0.696260317 
77F 0.36279431 0.259303302 0.714739164 
78V 0.7041921 0.502064824 0.712965713 
79F 0.58606732 0.476261199 0.812639066 
80S 0.61227983 0.475717515 0.776960941 
81L 0.52750337 0.340540469 0.645570222 
82G 0.33563405 0.239697993 0.714164701 
83K 0.511787 0.383677781 0.749682549 
84G 0.65550792 0.492196769 0.750863188 
85Q 0.47882631 0.338927388 0.707829495 
86V 0.79716527 0.590089977 0.740235426 
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Continuation of Table A3. Intensity Ratios for free FK1 vs. FK1 in the 
presence of tau  
87I 0.51127338 0.349425405 0.683441415 
88K 0.47088343 0.356784374 0.757691504 
89A 0.62463862 0.481520832 0.770879063 
90W 0.56601131 0.406965405 0.719005783 
91D 0.53528047 0.398370355 0.744227336 
92I 0.73629087 0.514921367 0.699345037 
93G 0.57586193 0.425936848 0.739650991 
94V 0.68403339 0.489171654 0.715128323 
95A 0.98531425 0.70143038 0.711884945 
96T 0.55311465 0.377688617 0.682839651 
97M 0.5972985 0.431293696 0.722073961 
98K 0.48438108 0.346046567 0.714409752 
99K 0.58455163 0.421291023 0.720707975 
100G 0.4949806 0.344621211 0.696231749 
101E 0.49696141 0.349454761 0.703182883 
102I 0.36563209 0.253906608 0.694431962 
103C 0.41093639 0.292154461 0.710948146 
104H 0.34284437 0.281994373 0.822514236 
105L 0.44519448 0.339602709 0.762818772 
106L 0.50184929 0.341067404 0.679621169 
107C 0.4289239 0.329630345 0.768505419 
110E 0.38721669 0.284746468 0.735367244 
111Y 0.43084106 0.37682122 0.87461771 
112A 0.5588764 0.411809951 0.736853363 
114G 0.25532582 0.194436908 0.761524646 
116A 0.44393265 0.355948061 0.801806442 
117G 0.02279598 0.017281402 0.758089861 
118S 0.16000305 0.115745857 0.723397813 
119L 0.02980269 0.019768994 0.663329083 
124S 0.49843192 0.369672626 0.741671251 
125N 0.41128477 0.268492132 0.652813206 
126A 0.35575125 0.254295707 0.714813256 
127T 0.22993352 0.165530533 0.719906067 
128L 0.37319833 0.265930682 0.712572005 
129F 0.30564055 0.216774046 0.709245051 
130F 0.47152317 0.349685639 0.741608609 
131E 0.38129213 0.302467048 0.793268522 
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Continuation of Table A3. Intensity Ratios for free FK1 vs. FK1 in the 
presence of tau  
132I 0.46471131 0.322362423 0.69368319 
133E 0.29698965 0.22830756 0.768739114 
134L 0.39588371 0.310977191 0.785526617 
135L 0.35332963 0.223280892 0.631933678 
136D 0.66940665 0.496039331 0.741013447 
137F 0.8076756 0.660482466 0.817757112 
138K 0.59618878 0.446191072 0.748405681 
139G 1.01781547 0.755611837 0.742385883 
140E 2.83270001 2.035108089 0.718434031 
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APPENDIX C: NMR Chemical Shift and Assignment Data for tau 
Table A4. Intensity Ratios for 15N-labeld tau titrations 
 AA 
Tau + 90 
Intensity Ratio 
Tau + 51 
Intensity Ratio 
Tau + 90 + 51 
Intensity Ratio 
1M       
2A       
E3       
P4       
R5 0.563655183 0.658731332 0.578663315 
Q6 0.460157933 0.62479062 0.60720268 
E7       
F8       
E9 0.291696578 0.647284039 0.496290979 
V10 0.583167132 0.542879936 0.389409653 
M11 0.574611611 0.588307441 0.44215045 
E12 0.47552297 0.505022726 0.331411172 
D13 0.595349033 0.537663304 0.388995034 
H14 0.463674434 0.532568351 0.342138174 
A15 0.498193206 0.658395567 0.373006504 
G16 0.519802432 0.508132211 0.366479352 
T17 0.538627593 0.641875652 0.510737134 
Y18 0.449016709 0.610605685 0.462978607 
G19 0.559082247 0.658529285 0.585855579 
I20       
G21 0.436700242 0.748491356 0.663125374 
D22 0.567556003 0.670443083 0.577604213 
R23 0.487961528 0.651487585 0.49052282 
K24       
D25 0.553988476 0.64829619 0.560346019 
Q26 0.512058185 0.693982329 0.551521772 
G27 0.536147707 0.581583296 0.406375753 
G28 0.572536794 0.690698879 0.591074938 
Y29       
T30 0.562178578 0.668818424 0.572901925 
M31       
H32 0.534912026 0.668999808 0.576730586 
Q33       
D34 0.530210685 0.632132948 0.54895138 
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
Q35       
E36 0.56364554 0.658786223 0.578682047 
G37 0.540518319 0.676012667 0.593583025 
D38 0.52366567 0.64614455 0.59703198 
T39 0.513005671 0.678593364 0.568288174 
D40       
A41       
G42 0.567761874 0.673543812 0.597310808 
L43 0.560018347 0.665717163 0.585296816 
K44       
A103       
E104 0.445088355 0.644056151 0.487154614 
E105       
A106       
G107 0.558889922 0.689501639 0.586248248 
I108 0.551368495 0.665175776 0.583784665 
G109 0.551876396 0.671613043 0.605936084 
D110 0.424753442 0.477912312 0.448711492 
T111 0.537138882 0.649388098 0.577753558 
112       
S113 0.549744388 0.68852623 0.586210755 
L114 0.578371186 0.662977863 0.492820283 
E115 0.448774455 0.625536309 0.445700906 
D116       
E117       
A118 0.349745502 0.625004721 0.424296242 
A119 0.541917558 0.662962808 0.578893661 
G120 0.56703789 0.694277866 0.604295003 
H121       
V122       
T123       
Q124       
A125       
R126       
M127 0.504458289 0.625181246 0.553374481 
V128       
S129 0.603656197 0.696015845 0.623544032 
K130 0.565956343 0.676893695 0.610068356 
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
S131 0.590029427 0.693342049 0.600704728 
K132 0.603616256 0.708629606 0.634291229 
D133 0.566055642 0.674855496 0.615224031 
G134 0.566535492 0.665288394 0.583902619 
T135 0.57423332 0.665499696 0.58816399 
G136 0.568181145 0.678885199 0.606178923 
S137 0.529434625 0.689675957 0.582795056 
D138 0.551656676 0.632037219 0.54518723 
D139       
K140 0.568476419 0.680863606 0.580947308 
K141       
A142 0.598062499 0.677845765 0.607356845 
K143 0.422647515 0.629791068 0.469616902 
G144 0.556534877 0.685344863 0.590757039 
A145 0.349431399 0.60563214 0.521752135 
D146 0.576517668 0.691794682 0.601718829 
G147 0.5922303 0.67276471 0.609747113 
K148 0.539992028 0.658482508 0.507697111 
T149       
K150 0.550540323 0.718219686 0.589699113 
I151       
A152 0.509092584 0.664094622 0.562504076 
T153 0.487434198 0.653958932 0.568438558 
P154       
R155 0.551594266 0.662633334 0.589034823 
G156 0.511503776 0.671057017 0.546000099 
A157 0.577101028 0.675945741 0.592793668 
A158 0.537443178 0.667139641 0.55807586 
P159       
P160       
G161 0.553195112 0.681041828 0.605174983 
Q162       
K163 0.507109564 0.6504144 0.563726664 
G164 0.506787813 0.66799362 0.56275482 
Q165       
A166 0.605322565 0.727961696 0.62627316 
N167 0.594227721 0.706589746 0.618050969 
A168       
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
T169 0.566722283 0.66140803 0.572126938 
R170 0.597489209 0.710107383 0.61710168 
I171 0.482639524 0.663946012 0.532088793 
P172       
A173 0.509800668 0.657918441 0.536828667 
K174 0.395378692 0.628769507 0.426913917 
T175 0.570705621 0.628422873 0.544523096 
P176       
P177       
A178 0.413361394 0.642921182 0.446280626 
P179       
K180       
T181 0.612909756 0.699943911 0.59927901 
P182       
P183       
S184       
S185 0.594227721 0.706589746 0.618050969 
G186 0.544894423 0.613984487 0.484690421 
E187 0.414693092 0.623085602 0.478537691 
P188       
P189       
K190 0.476678925 0.569112311 0.475700468 
S191 0.556191116 0.679428203 0.588657044 
G192 0.62370398 0.743249153 0.680065286 
D193       
R194 0.518990504 0.663443077 0.561588812 
S195 0.557333958 0.701110151 0.588434201 
G196 0.550528837 0.736893123 0.566782599 
Y197       
S198 0.544368672 0.677999565 0.560565635 
S199 0.457921878 0.637167342 0.520607072 
P200       
G201 0.570129462 0.75956661 0.6388008 
S202 0.516120201 0.635255902 0.530996708 
P203       
G204 0.552789084 0.724999522 0.599358228 
T205 0.530481576 0.671387238 0.565259229 
P206       
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
G207 0.545350495 0.687574623 0.610548883 
S208 0.527429056 0.641822794 0.563684105 
R209       
S210 0.563634131 0.711116306 0.612867112 
R211       
T212 0.415590361 0.596324992 0.43763959 
P213       
S214 0.482848234 0.645150218 0.518390128 
L215 0.452609778 0.626211309 0.498394316 
P216       
T217       
P218       
P219       
T220 0.566649832 0.681633559 0.619838898 
R221 0.40647401 0.61474607 0.499717459 
E222 0.454145141 0.667921287 0.504390029 
P223       
K224       
K225       
V226 0.346086361 0.604781649 0.40628609 
A227 0.359948081 0.598244408 0.408461516 
V228 0.355216062 0.565082854 0.376813031 
V229       
R230 0.401542827 0.604954645 0.398035655 
T231       
P232       
P233       
K234       
S235 0.447297223 0.615558512 0.443244808 
P236       
S237 0.522586604 0.657102734 0.571724571 
S238 0.445098455 0.648321167 0.449158192 
A239 0.459908207 0.626949161 0.482924848 
K240       
S241 0.485981005 0.650589499 0.529372205 
R242       
L243 0.429900947 0.639063778 0.449124618 
Q244       
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
T245 0.453201279 0.626363001 0.479075647 
A246 0.469928561 0.629553852 0.514396308 
P247       
V248       
P249       
M250 0.411257788 0.607036898 0.446195771 
P251       
D252 0.324657967 0.599545518 0.403455394 
L253       
K254       
N255 0.411642211 0.591885646 0.454633287 
V256 0.443612455 0.621998509 0.464536248 
K257 0.524446213 0.610280502 0.521093484 
S258       
K259       
I260 0.502893749 0.65440416 0.539792697 
G261 0.425336919 0.609169162 0.494913644 
S262 0.541750439 0.650972989 0.562556083 
T263 0.522765395 0.673376015 0.590245693 
E264       
N265       
L266 0.508323477 0.657839414 0.525154101 
K267       
H268       
Q269       
P270       
G271 0.543593373 0.659608234 0.558650108 
G272       
G273 0.533698415 0.68950265 0.664419406 
K274 0.552813175 0.642916019 0.557096169 
V275 0.328242716 0.303893994 0.179598568 
Q276 0.232490192 0.554065555 0.2944053 
I277 0.166476233 0.298956991 0.190141179 
I278 0.149322538 0.285999852 0.187642473 
N279 0.296233689 0.599237798 0.350953245 
K280 0.501265277 0.522646135 0.33260292 
K281 0.533697923 0.682775483 0.601790718 
L282 0.354495834 0.633083251 0.400653602 
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
D283 0.615849087 0.663583209 0.570223714 
L284 0.531738081 0.703859892 0.532063571 
S285 0.403026007 0.608751058 0.435794052 
N286 0.500440509 0.676943173 0.548128063 
V287 0.350227351 0.57827035 0.390243163 
Q288 0.464021612 0.614337205 0.512778453 
S289 0.556191116 0.679428203 0.588657044 
K290 0.529195452 0.670828456 0.565762485 
C291 0.544341454 0.664913065 0.560007275 
G292 0.610744855 0.738800491 0.609777696 
S293 0.523254302 0.632495159 0.544273357 
K294 0.538924143 0.66977247 0.584696434 
D295       
N296 0.404845368 0.651322665 0.432691177 
I297 0.335505195 0.63021978 0.493269806 
K298 0.425620885 0.679372784 0.541556199 
H299 0.532065483 0.658212085 0.537649048 
V300 0.499885122 0.672829256 0.528301762 
P301       
G302 0.47320917 0.645367435 0.51044059 
G303       
G304       
S305 0.538926479 0.662941725 0.555327943 
V306 0.428650504 0.634195242 0.437174349 
Q307 0.383467356 0.601611936 0.43335407 
I308 0.188096108 0.532463285 0.203248975 
V309 0.146717661 0.528840905 0.181544525 
Y310 0.160285407 0.563115243 0.217823265 
K311 0.163175808 0.543293711 0.197567621 
P312       
V313 0.151091477 0.541326913 0.183414719 
D314 0.203608125 0.570160133 0.25248624 
L315       
S316 0.267749485 0.526825628 0.29980627 
K317 0.298531162 0.569336575 0.293421162 
V318 0.330999239 0.5608154 0.33546162 
T319 0.420713892 0.631633207 0.452067545 
S320 0.414710682 0.63656025 0.448679157 
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
K321       
C322 0.467519529 0.660275481 0.531378483 
G323 0.489275924 0.640349697 0.475143965 
S324 0.388179152 0.504397611 0.399054019 
L325 0.458781294 0.63038341 0.483641494 
G326 0.491461765 0.653021784 0.509876051 
N327 0.518571356 0.654046664 0.535676125 
I328 0.598809443 0.697776557 0.609396097 
H329       
H330 0.564693244 0.426873664 0.380315951 
K331 0.60904554 0.641128443 0.478119992 
P332       
G333 0.392590567 0.630739536 0.445482845 
G334       
G335       
Q336 0.546936142 0.661146792 0.477218683 
V337       
E338 0.44585054 0.64159492 0.491862908 
E339 0.448919849 0.633266318 0.481675293 
K340 0.493528207 0.660870962 0.509104723 
S341 0.456663737 0.661584532 0.48936215 
E342 0.453296573 0.638764547 0.49071746 
K343 0.428801154 0.57739353 0.448345414 
L344 0.507322395 0.655779485 0.53710633 
D345 0.535519344 0.658283005 0.558377344 
F446 0.471041939 0.663040233 0.518455501 
K347 0.416857139 0.618689679 0.474791039 
D348       
R349 0.321223414 0.527280974 0.342991499 
V350 0.399370727 0.567926277 0.388698787 
Q351 0.365010646 0.569632043 0.387227139 
S352 0.446566923 0.595543186 0.44790599 
K353 0.449156455 0.572022195 0.453492793 
I354 0.351530256 0.562181365 0.361210785 
G355 0.49132283 0.615320429 0.475280613 
S356 0.475671815 0.639146465 0.515519549 
L357 0.424267449 0.604638394 0.449275441 
D358 0.43273195 0.549341142 0.41237699 
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
N359 0.504613582 0.640518412 0.535242631 
I360 0.361139253 0.580864999 0.398868583 
T361 0.515218207 0.667185972 0.550807169 
H362       
V363 0.406689718 0.558753961 0.465253255 
P364       
G365 0.412679947 0.655986541 0.539037108 
G366       
G367       
N368 0.567335505 0.72388699 0.617084665 
K369 0.507695885 0.659890078 0.542653219 
K370 0.491763689 0.651592485 0.529374545 
I371 0.490938496 0.603960977 0.498559205 
E372 0.378705754 0.630622456 0.45028864 
T373       
H374       
K375 0.504265979 0.671113396 0.540766243 
L376 0.448919849 0.633266318 0.481675293 
T377 0.363676437 0.606673997 0.391807232 
F378       
R379 0.413351769 0.625096872 0.460747293 
E380 0.535864867 0.628196487 0.544263814 
N381 0.450502428 0.639920175 0.482877291 
A382 0.569392179 0.672179852 0.576140417 
K383       
A384 0.40980873 0.637745344 0.470418426 
K385 0.462514678 0.686147896 0.551762933 
T386 0.450773072 0.62670671 0.434457193 
D387       
H388       
G389 0.634786782 0.724364809 0.639258417 
A390 0.512951935 0.668398442 0.534282064 
E391       
I392 0.364842462 0.616658732 0.391910891 
V393 0.509978002 0.645306464 0.56601639 
Y394 0.413744802 0.627735012 0.423195452 
K395 0.438448266 0.654688033 0.472225107 
S396       
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
P397 0.344966644 0.663184431 0.706295335 
V398 0.430171004 0.636208595 0.461482216 
V399 0.551851519 0.683704991 0.596380141 
S400       
G401       
D402 0.530700928 0.656275842 0.568277706 
T403       
S404 0.563520086 0.701563194 0.56575212 
P405       
R406 0.4514698 0.592643755 0.428245951 
H407       
L408       
S409 0.485864546 0.668404577 0.542346318 
N410 0.517918988 0.610497553 0.568670044 
V411 0.460781816 0.624058255 0.44894193 
S412       
S413 0.578292195 0.674343973 0.562925046 
T414 0.549572028 0.677406373 0.563870896 
G415 0.511127688 0.682041939 0.547359624 
S416 0.531782543 0.685823594 0.568646242 
I417       
D418       
M419       
V420 0.495895998 0.662465563 0.562302699 
D421 0.539203845 0.637229433 0.54066344 
S422 0.499960853 0.664395663 0.520364219 
P423       
Q424 0.473870296 0.636294572 0.490784143 
I425       
A426 0.564700954 0.682193855 0.602583863 
T427 0.438093782 0.630953658 0.441377421 
L428 0.384770812 0.63494548 0.397617852 
A429 0.426516113 0.623821569 0.458194268 
D430 0.403850998 0.62479308 0.424794774 
E431 0.358545494 0.565444167 0.394454207 
V432 0.3876424 0.630789588 0.42022285 
S433 0.488222259 0.619148747 0.531440583 
A434 0.417916758 0.652867025 0.419805706 
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Continuation of Table A4. Intensity Ratios for 15N-labeld tau titrations 
S435       
L436 0.43366129 0.616457457 0.429287907 
437 0.453728278 0.624593377 0.433832448 
K438       
Q439       
G440 0.503750436 0.628980282 0.480989264 
L441 0.4553879 0.611834579 0.446429996 
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Table A5. Intensity Ratio Plot Averages and Standard Deviation Values 
AVERAGES tau + Hsp90 
  (270-441) (1-40) (1-441) 
MEAN 0.45145733 0.51880157 0.48144882 
STDEV 0.10274495 0.06254841 0.0924332 
        
AVERAGES tau + FKBP51 
  (270-441) (1-40) (1-441) 
MEAN 0.6328808 0.62887167 0.64189832 
STDEV 0.04992598 0.06128861 0.04977791 
        
AVERAGES tau + Hsp90 + FKBP51 
  (270-441) (1-40) (1-441) 
MEAN 0.47757278 0.51885178 0.50760078 
STDEV 0.10098332 0.11848967 0.09631686 
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APPENDIX D: Full length Intensity Ratio Plots for tau titrations 
 
Figure A2: Full length Intensity Ratio Plots for tau titrations. Intensity ratio plots for 15N-
labeled tau in the presence of Hsp90 and/or FKBP51. The two regions that experience the largest 
reductions are two hydrophobic hexapeptide regions, V275 – K280 and V306 – K311. Some 
residues in the N-terminus also undergo significant reductions. The pink line on each plot 
indicates one standard deviation below the mean and was calculated from the average intensity 
ratios for all assigned residues. 
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